

Prof. Elio Scarpini

CURRICULUM VITAE

Luogo e data di nascita: Milano, 12 luglio 1952

Cittadinanza: Italiana

Titoli di studio

1971: Diploma Maturità Classica

1977: Laurea Medicina e Chirurgia (110/110 e lode) presso l'Università degli Studi di Milano.

1977: Abilitazione professione Medico Chirurgo presso l'Università degli Studi di Milano

1981: Specializzazione in Neurologia (70/70 e lode) presso l'Università degli Studi di Milano.

1989: Idoneità Nazionale per Primario nella disciplina Neurologia

Esperienza professionale

1980-oggi: lavora presso il Dipartimento di Scienze Neurologiche, Università di Milano, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico.

Attualmente responsabile dell'Unità Valutativa Alzheimer, del Centro Sclerosi Multipla e dei relativi laboratori di Genetica e Biologia Molecolare.

Capo Reparto Degenza e Responsabile del Day Hospital e del Laboratorio di Biochimica Clinica dell'UO Neurologia

2002: Incarico dirigenziale "Professionale con elevata autonomia tecnico-professionale", U.O. Neurologia, Dipartimento di Scienze Neurologiche, IRCCS Ospedale Maggiore Policlinico di Milano

2003: Responsabile UOS Malattie Neurodegenerative e Demielinizzanti dell'IRCCS Fondazione Cà Granda

2007: Professore Associato di Neurologia, Facoltà di Medicina e Chirurgia, Università di Milano.

2009-oggi: Titolare dell'insegnamento di Neurologia per il corso di laurea Magistrale in Odontoiatria e Protesi Dentaria

Ricerca Scientifica

Inizialmente su malattie neuromuscolari e patologie del sistema nervoso periferico. Nel 1985, soggiorno di studio annuale presso il Laboratorio di Neuroimmunologia, Dept. of Neurology, University of Pennsylvania, Philadelphia (U.S.A.), diretto dal prof. R.P. Lisak. Successivamente, ricerca di base sugli aspetti infiammatori e genetici della malattia di Alzheimer e demenze correlate e sulla Sclerosi Multipla.

Ha partecipato come investigatore a numerose ricerche cliniche su Alzheimer e Sclerosi Multipla, in alcuni casi come investigatore principale e centro coordinatore dello studio.

Partecipazione a Società scientifiche e gruppi di ricerca

Società Italiana di Neurologia

Associazione Italiana di Neuropatologia

Gruppo per lo Studio delle Neuropatie Periferiche

Gruppo di Metodologia del Progetto Finalizzato Invecchiamento del CNR

Società Italiana di Neuroimmunologia

Associazione Italiana Ricerca Invecchiamento Cerebrale

Centro d'Eccellenza per le Malattie Neurodegenerative dell'Università di Milano

American Academy of Neurology

European Neurological Society

Dal 1998 membro del Comitato Scientifico dell'Associazione Italiana Sclerosi Multipla-FISM

Dal 2000 Membro del Consiglio Scientifico del Centro Dino Ferrari dell'Università di Milano

Nel 2000 membro del Comitato Internazionale per la Verifica della Diagnosi della ricerca Multicentrica Internazionale sull'effetto della Rivastigmina (Exelon, Novartis) nella malattia di Alzheimer.

Dal 2006 membro eletto dell'Executive Committee della Società Europea di Neurologia (ENS) e responsabile dell'organizzazione dei "teaching courses" sulle Demenze nell'ambito del congresso annuale della Società

Dal 2004 membro del Consiglio Scientifico del Centro d'Eccellenza per le Malattie Neurodegenerative dell'Università di Milano

Nel 2005 Socio Fondatore dell'Associazione Italiana per lo Studio delle demenze afferente alla Società Italiana di Neurologia (SINDEM)

Dal 2009, Segretario dell'Associazione Italiana per lo Studio delle demenze afferente alla Società Italiana di Neurologia (SINDEM)

Dal 2007 Coordinatore del Gruppo di Approfondimento Tecnico (GAT) Regionale per le Patologie Neurologiche Progressive - Sottogruppo Demenze: "Percorso diagnostico, terapeutico ed assistenziale". Decreto Regione Lombardia n. 9942 del 5/10/2009

Dal 2010 Membro del Consiglio Amministrativo della Fondazione Italo Monzino (con il prof Enrico Decleva ed il prof Silvio Garattini)

Editorial board di riviste internazionali

Membro dell'Editorial Board di:

- Journal of Neurology
- Therapy

Associate Editor di:

- Journal of Alzheimer's disease
- Journal of the Neurological Sciences

Revisore di riviste internazionali

Journal of Neurology

Journal of the Neurological Sciences

Neurology

Trends in Neuroimmunology

Journal of Neuroimmunology

Neuroscience Letters

European Journal of Neurology

Lancet Neurology

Organizzazione eventi scientifici

Congressi e simposi organizzati personalmente nel corso degli ultimi anni:

- XXXVII Annual Meeting of the Italian Neuropathological Association, Teaching course on demyelinating diseases “Demyelination in PNS and CNS: basic mechanisms and advances in treatment” May 23, 2001, Verbania, Italy
- A tribute to Professor Guglielmo Scarlato - “Immunology of Multiple Sclerosis: from molecular pathogenesis to treatment” – 1 febbraio 2003, Milan, Italy.
- Patogenesi e clinica delle malattie demielinizzanti – Corso biennale residenziale
I anno: Aspetti patogenetici e diagnostici – 2-5 Marzo 2004, Milano
II anno: Aspetti prognostici e terapeutici – 2-4 Marzo 2005, Milano
- Giornata monotematica del Centro di Eccellenza per le Malattie Neurodegenerative dal titolo: “Nuove acquisizioni nella neurobiologia della malattia di Alzheimer: implicazioni pratiche per una diagnosi ed un trattamento precoci” – Milano, 28 Ottobre 2006.
- “Demenza di Alzheimer e malattia di Parkinson”- Milano, 25 Novembre 2010
- VII Congresso Annuale della Associazione Italiana per lo studio delle Demenze afferente alla Società Italiana di Neurologia (SINdem) – Milano, 17-19 Marzo 2011

PUBBLICAZIONI SU RIVISTE INTERNAZIONALI CENSITE

1. Caccia MR, Cerri C, Gravame V, Meola G, Pagni R, Scarlato G, Scarpini E. Myopathy with paroxysmal myoglobinuria and focal muscle necrosis following enflurane anaesthesia. **Journal of the Neurological Sciences** 1978; 39(1): 61-69.
2. Scarlato G, Meola G, Scarpini E, Cerri C. Muscular carnitine synthesis and palmitate metabolism in vitro. **Journal of Neurology** 1978; 218(3):149-156.
3. Meola G, Manfredi L, Scarpini E, Dall'Oglio P, Mariani C, Scarlato G. Pentazocine-induced neuromuscular syndrome: clinical, histochemical features in two cases and a tissue culture study of pentazocine-block myogenesis in human foetal muscle. **Basic and Applied Histochemistry** 1980; 24(3): 193-202.
4. Meola G, Scarpini E, Silani V, Scarlato G. Manifesting carrier of x-linked Duchenne muscular dystrophy. **Journal of the Neurological Sciences** 1981; 49(3): 455-463.
5. Meola G, Scarpini E, Manfredi L, Mariani C, Scarlato G. Pentazocine-blocked myogenesis in human foetal muscle cultures. **Acta Neuropathologica Suppl (Berl)**. 1981; 7: 310-312.
6. Scarpini E, Meola G, Baron P, Moggio M, Silani V, Scarlato G. Morphological studies and quantitative assessment of the effect of chick embryo extract on monolayer cultures of normal human muscle. **Acta Neurologica (Napoli)**. 1982; 4(6): 403-410.
7. Meola G, Scarpini E, Minetti C, Cordone G, Scarlato G. Clinical and histomorphological study of congenital myopathy with minimal lesions. **Minerva Pediatrica** 1982; 34(21): 891-896.
8. Meola G, Manfredi L, Scarpini E, Moggio M, Pellegrini G, Scarlato G. Cytochemical and ultrastructural studies of human foetal muscle in culture. **Acta Neurologica (Napoli)** 1983; 5(2): 85-95.
9. Biral D, Damiani E, Margreth A, Scarpini E. Myosin subunit composition in human developing muscle. **Biochemistry Journal** 1984; 224(3): 923-931.
10. Dalla Libera L, Scarpini E, Manfredi L, Marini A. Urinary 3-methylhistidine output in newborn human infants. **Muscle & Nerve** 1984; 7(6): 494-495.

11. Minetti C, Meola G, Scarpini E, Cordone G, Bado M, Scarlato G. The myopathy of congenital fiber type disproportion. **Minerva Pediatrica** 1984; 36(4): 181-187.
12. Meola G, Scarpini E, Manfredi L, Velicogna M, Pellegrini G, Redi CA, Scarlato G. Infantile-acute acid maltase deficiency (Pompe's disease): studies of muscle cultures. **Basic and Applied Histochemistry** 1984; 28(3): 245-255.
13. Biral D, Damiani E, Margreth A, Scarpini E, Scarlato G. Slow myosin heavy chain isozyme in nemaline myopathy. **Neurology** 1985; 35(9): 1360-1363.
14. Ross AH, Pleasure D, Sonnenfeld K, Atkinson B, Kreider B, Jackson DM, Taff I, Scarpini E, Lisak RP, Koprowski H. Expression of melanoma-associated antigens by normal and neurofibroma Schwann cells. **Cancer Research** 1986; 46(11): 5887-5892.
15. Scarpini E, Meola G, Baron P, Beretta S, Velicogna M, Scarlato G. S-100 protein and laminin: immunocytochemical markers for human Schwann cells in vitro. **Experimental Neurology** 1986; 93(1): 77-83.
16. Meola G, Scarpini E, Velicogna M, Scarlato G, Larizza L, Conti AF. Cytogenetic analysis and muscle differentiation in a girl with severe muscular dystrophy. **Journal of Neurology** 1986; 233(3): 168-70.
17. Meola G, Scarpini E, Velicogna M, Mottura A, Baron PL, Beretta S, Scarlato G. Analysis of fibronectin expression during human muscle differentiation. **Basic and Applied Histochemistry** 1986; 30(2): 153-163.
18. Biral D, Damiani E, Scarpini E, Bet L, Bresolin N, Moggio M, Pellegrini G, Barbieri S, Scarlato G. Biochemical and immunologic studies in a case of congenital myopathy with unusual morphologic features. **Neurology** 1987; 37(10): 1658-1662.
19. Scarpini E, Meola G, Baron PL, Beretta S, Velicogna M, Moggio M, Buscaglia M, Doronzo R, Scarlato G. Human Schwann cells: cytochemical, ultrastructural and immunological studies in vivo and in vitro. **Basic and Applied Histochemistry** 1987; 31(1): 33-42.
20. Scarpini E, Kreider BQ, Lisak RP, Pleasure DE. Establishment of Schwann cell cultures from adult rat peripheral nerves. **Experimental Neurology** 1988; 102(2): 167-176.
21. Scarpini E, Kreider BQ, Lisak RP, Meola G, Velicogna ME, Baron P, Beretta S, Buscaglia M, Ross AH, Scarlato G. Cultures of human Schwann cells isolated from fetal nerves. **Brain Research** 1988; 440(2): 261-266.
22. Scarpini E, Ross AH, Rosen JL, Brown MJ, Rostami A, Koprowski H, Lisak RP. Expression of nerve growth factor receptor during human peripheral nerve development. **Developmental Biology** 1988; 125(2): 301-310.
23. Bresolin N, Monza G, Scarpini E, Scarlato G, Straneo G, Martinazzoli A, Beninca G, Cattoni C, De Candia R, Belloni G, et al. Treatment of anxiety with ketazolam in elderly patients. **Clinical Therapy** 1988; 10(5): 536-542.
24. Scarpini E, Baron PG, Bet L, Bottini G, Bresolin N, Meola G, Pezzoli G, Vallar G, Monza GC, Scarlato G. Low doses of ketazolam in anxiety: a double-blind, placebo-controlled study. **Neuropsychobiology** 1988; 20(2): 74-77.
25. Scarpini E, Beretta S, Ross AH, Moggio M, Jann S, Pleasure D, Scarlato G. Rapid quantitative immunohistochemical assessment of human peripheral neuropathies using a monoclonal antibody against nerve growth factor receptor. **Journal of Neurology** 1989; 236(8): 439-444.
26. Biral D, Scarpini E, Angelini C, Salviati G, Margreth A. Myosin heavy chain composition of muscle fibers in spinal muscular atrophy. **Muscle & Nerve** 1989; 12(1): 43-51.
27. Moggio M, Bresolin N, Scarpini E, Adobbati L, Prella A, Gallanti A, Bet L, Fortunato F, Pellegrini G, Scarlato G. Cytochrome c oxidase during human fetal development. **International Journal of Developmental Neuroscience**. 1989; 7(1): 5-14.

28. Scarpini E, Lisak RP, Beretta S, Velicogna M, Doronzo R, Moggio M, Jann S, Scarlato G. Quantitative assessment of class II molecules in normal and pathological nerves. Immunocytochemical studies in vivo and in tissue culture. **Brain** 1990; 113 (Pt 3): 659-75.
29. Vedeler CA, Scarpini E, Beretta S, Doronzo R, Matre R. The ontogenesis of Fc gamma receptors and complement receptors CR1 in human peripheral nerve. **Acta Neuropathologica** (Berl) 1990; 80(1): 35-40.
30. Scarpini E, Sacilotto G, Lazzarin A, Geremia L, Doronzo R, Scarlato G. Acute ataxia coincident with seroconversion for anti-HIV. **Journal of Neurology** 1991; 238(6): 356-357.
31. Prelle A, Chianese L, Moggio M, Gallanti A, Sciacco M, Checcarelli N, Comi G, Scarpini E, Bonilla E, Scarlato G. Appearance and localization of dystrophin in normal human fetal muscle. **International Journal of Developmental Neuroscience** 1991; 9(6): 607-612.
32. Baron PL, Meola G, Scarpini E, Moggio M, Santilli I, Scarlato G. Lysosomotropic agents induce morphological and functional changes in human muscle cells in vitro. **European Journal of Basic and Applied Histochemistry** 1991; 35(4): 423-432.
33. Bottini G, Vallar G, Cappa S, Monza GC, Scarpini E, Baron P, Cheldi A, Scarlato G. Oxiracetam in dementia: a double-blind, placebo-controlled study. **Acta Neurologica Scandinava** 1992; 86(3): 237-341.
34. Gallanti A, Prelle A, Chianese L, Barbieri S, Jann S, Schiaffino S, Comini A, Scarpini E, Pellegrini G, Moggio M, et al. Congenital myopathy with type 2A muscle fiber uniformity and smallness. **Neuropediatrics** 1992; 23(1): 10-13.
35. Sciacco M, Scarpini E, Baron PL, Doronzo R, Moggio M, Passerini D, Scarlato G. Sural nerve immunoreactivity for nerve growth factor receptor in a case of localized hypertrophic neuropathy. **Acta Neuropathologica** (Berl). 1992;83(5):547-53.
36. Scarpini E, Doronzo R, Baron P, Moggio M, Basellini A, Scarlato G. Phenotypic and proliferative properties of Schwann cells from nerves of diabetic patients. **International Journal of Clinical and Pharmacological Research** 1992; 12(5-6): 211-215.
37. Scarpini E, Bianchi R, Moggio M, Sciacco M, Fiori MG, Scarlato G. Decrease of nerve Na⁺,K⁽⁺⁾-ATPase activity in the pathogenesis of human diabetic neuropathy. **Journal of the Neurological Sciences** 1993; 120(2): 159-167.
38. Conti AM, Malosio ML, Scarpini E, Di Giulio AM, Scarlato G, Mantegazza P, Gorio A. Myelin protein transcripts increase in experimental diabetic neuropathy. **Neuroscience Letters** 1993; 161(2): 203-206.
39. Baron P, Constantin G, D'Andrea A, Ponzin D, Scarpini E, Scarlato G, Trinchieri G, Rossi F, Cassatella MA. Production of tumor necrosis factor and other proinflammatory cytokines by human mononuclear phagocytes stimulated with myelin P2 protein. **Proc Natl Acad Sci U. S. A.** 1993; 90(10): 4414-4418.
40. Baron P, Kamholz J, Scherer S, Honda H, Shy M, Scarpini E, Scarlato G, Pleasure D. Appearance of PLP mRNA in specific regions of the developing rat lumbosacral spinal cord as revealed by in situ hybridization. **Experimental Neurology** 1993; 121(1): 139-147.
41. Maggi S, Zucchetto M, Grigoletto F, Baldereschi M, Candelise L, Scarpini E, Scarlato G, Amaducci L. The Italian Longitudinal Study on Aging (ILSA): design and methods. **Aging** (Milano). 1994; 6(6):464-473.
42. Bet L, Moggio M, Comi GP, Mariani C, Prelle A, Checcarelli N, Bordoni A, Bresolin N, Scarpini E, Scarlato G. Multiple sclerosis and mitochondrial myopathy: an unusual combination of diseases. **Journal of Neurology** 1994; 241(8): 511-516.
43. Baron P, Scarpini E, Meola G, Santilli I, Conti G, Pleasure D, Scarlato G. Expression of the low-affinity NGF receptor during human muscle development, regeneration, and in tissue culture. **Muscle & Nerve** 1994; 17(3): 276-284.
44. Laudanna C, Constantin G, Baron P, Scarpini E, Scarlato G, Cabrini G, Dechecchi C, Rossi F, Cassatella MA, Berton G. Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor-alpha and interleukin-8 mRNA in human

- neutrophils. Evidence for a role of L-selectin as a signaling molecule. **Journal of Biological Chemistry** 1994; 269(6): 4021-4026.
45. Conti G, Baron PL, Scarpini E, Vedeler C, Rostami A, Pleasure D, Scarlato G. Low-affinity nerve growth factor receptor expression in sciatic nerve during P2-peptide induced experimental allergic neuritis. **Neuroscience Letters** 1995; 199(2): 135-138.
 46. Conti AM, Scarpini E, Malosio ML, Di Giulio AM, Baron P, Scarlato G, Mantegazza P, Gorio A. In situ hybridization study of myelin protein mRNA in rats with an experimental diabetic neuropathy. **Neuroscience Letters** 1996 Mar 22; 207(1): 65-69.
 47. Scarpini E, Doneda P, Pizzul S, Chiodi P, Ramacci MT, Baron P, Conti G, Sacilotto G, Arduini A, Scarlato G. L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects. **Journal of the Peripheral Nervous System** 1996; 1(2): 157-163.
 48. Scarpini E, Conti G, Chianese L, Baron P, Pizzul S, Basellini A, Livraghi S, Scarlato G. Induction of p75NGFR in human diabetic neuropathy. **Journal of the Neurological Sciences** 1996; 135(1): 55-62.
 49. Baron P, Scarpini E, Pizzul S, Zotti F, Conti G, Pleasure D, Scarlato G. Immunocytochemical expression of human muscle cell p75 neurotrophin receptor is down-regulated by cyclic adenosine 3',5'-monophosphate. **Neuroscience Letters** 1997; 234(2-3): 79-82.
 50. Conti G, Stoll G, Scarpini E, Baron PL, Bianchi R, Livraghi S, Scarlato G. p75 neurotrophin receptor induction and macrophage infiltration in peripheral nerve during experimental diabetic neuropathy: possible relevance on regeneration. **Experimental Neurology** 1997; 146(1): 206-211.
 51. Scarpini E, Sacilotto G, Baron P, Cusini M, Scarlato G. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. **Journal of the Peripheral Nervous System** 1997; 2(3): 250-252.
 52. Conti G, Scarpini E, Rostami A, Livraghi S, Baron PL, Pleasure D, Scarlato G. Schwann cell undergoes apoptosis during experimental allergic neuritis (EAN). **Journal of the Neurological Sciences** 1998; 161(1): 29-35.
 53. Baron P, Constantin G, Meda L, Scarpini E, Scarlato G, Trinchieri G, Monastra G, Rossi F, Cassatella MA. Cultured human monocytes release proinflammatory cytokines in response to myelin basic protein. **Neuroscience Letters** 1998; 252(3): 151-154.
 54. Rossi G, Macchi G, Porro M, Giaccone G, Bugiani M, Scarpini E, Scarlato G, Molini GE, Sasanelli F, Bugiani O, Tagliavini F. Fatal familial insomnia: genetic, neuropathologic, and biochemical study of a patient from a new Italian kindred. **Neurology** 1998;50(3): 688-692.
 55. Galimberti D, Baron PL, Meda L, Prat E, Scarpini E, Delgado R, Catania A, Lipton JM, Scarlato G. α -MSH peptides inhibit production of nitric oxide and tumor necrosis factor- α by microglial cells activated with β -amyloid and interferon- γ . **Biochemical and Biophysical Research Communications** 1999;263:251-256.
 56. Scarpini E, Conti GC, Bussini S, Clerici R, Siglienti I, Piccio L, De Pol A, Baron PL, Scarlato G. Human schwann cell proliferation and IL-6 production following TNF-alpha stimulation in vitro. **Ann N Y Acad Sci** 1999; 883: 520-522.
 57. Vedeler CA, Conti G, Fujioka T, Scarpini E, Rostami A. The expression of CD59 in experimental allergic neuritis. **Journal of the Neurological Sciences** 1999; 165(2): 154-159.
 58. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. **Journal of Neuroimmunology** 1999; 93(1-2): 45-52.
 59. Cavanna B, Carpo M, Pedotti R, Scarpini E, Meucci N, Allaria S, Scarlato G, Nobile-Orazio E. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. **Journal of Neuroimmunology** 1999; 94(1-2): 157-164.

60. Conti G, Scarpini E, Rostami A, Livraghi S, Clerici R, Piccio L, Siglienti I, Baron PL, Pleasure D, Scarlato G. Schwann cell apoptosis during cell-mediated demyelination. **Ann N Y Acad Sci** 1999 Sep 14;883:518-519.
61. Constantin G, Piccio L, Bussini S, Pizzuti A, Scarpini E, Baron P, Conti G, Pizzul S, Scarlato G. Induction of adhesion molecules on human schwann cells by proinflammatory cytokines, an immunofluorescence study. **Journal of the Neurological Sciences** 1999; 170(2): 124-30.
62. Prat E, Baron P, Meda L, Scarpini E, Galimberti D, Ardolino G, Catania A, Scarlato G. The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP-1) upon stimulation with β -amyloid protein. **Neuroscience Letters** 2000;283:177-180.
63. Bazzi P, Tancredi L, Scarpini E, Messina S, Sciacco M, Livraghi S, Vanoli M, Prella A, Scarlato G, Moggio M. Severe polyneuropathy in a patient with Churg-Strauss syndrome. **Journal of the Peripheral Nervous System** 2000; 5(2): 106-110.
64. Baron PL, Galimberti D, Meda L, Prat E, Scarpini E, Conti G, Moggio M, Prella A, Scarlato G. Synergistic effect of β -amyloid protein and Interferon- γ or nitric oxide production by C2C12 muscle cells. **Brain** 2000;123:374-379.
65. Baron P, Galimberti D, Meda L, Scarpini E, Conti G, Cogiamanian F, Scarlato G. Production of IL-6 by human myoblasts stimulated with A β : relevance in the pathogenesis of IBM. **Neurology** 2001;57:1561-1565.
66. Clerici R, Conti G, Scarpini E, De Riz M, Baron PL, Scarlato G. Visual loss and enlarged extraocular muscles from metastatic signet ring carcinoma. *Journal of Neurology* 2001; 248(4): 336-338.
67. Rigamonti AE, Pincelli AI, Corrà B, Viarengo R, Bonomo SM, Galimberti D, Scacchi M, Scarpini E, Cavagnini F, Müller EE. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. **Journal of Endocrinology** 2002;175:R1-5.
68. Conti G, Scarpini E, Baron P, Livraghi S, Tiriticco M, Bianchi R, Vedeler C, Scarlato G. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1beta and p75NTR. **Journal of the Neurological Sciences** 2002; 195(1): 35-40.
69. Piccio L, Rossi B, Scarpini E, Laudanna C, Giagulli C, Issekutz AC, Vestweber D, Butcher EC, Constantin G. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. **Journal of Immunology** 2002; 168(4): 1940-1949.
70. Scarpini E, Galimberti D, Baron PL, Clerici R, Ronzoni M, Conti G, Scarlato G. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. **Journal of the Neurological Sciences** 2002;195: 41-46.
71. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. **Lancet Neurology** 2003 ; 2(9): 539-547.
72. Micco A, Nobile-Orazio E, Baron P, Conti G, Napoli L, Serafini M, Scarlato G, Scarpini E. Severe chronic sensory-motor polyneuropathy: coexistence of 3 unrelated etiologies in a type 1 diabetic patient. A case report and review of the literature. **Journal of the Peripheral Nervous System** 2003; 8(1):23-28.
73. Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, Ottoboni L, Ciabini D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. **Blood** 2003; 101(12): 4775-4782.
74. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P, on behalf of the DIAR Group. Chemokines in CSF and serum from patients with different types of dementia. **Annals of Neurology** 2003; 53: 547-548.

75. Galimberti D, Bresolin N, Scarpini E. Chemokine network in Multiple Sclerosis: role in the pathogenesis and targeting for future treatments. **Expert Reviews Neurotherapeutics** 2004; 4(3): 89-103.
76. Conti G, Rostami A, Scarpini E, Baron P, Galimberti D, Bresolin N, Contri M, Palumbo C, De Pol A. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. **Experimental Neurology** 2004;187: 350-358.
77. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, Tiriticco M, Mariani C, Forloni G, Pettenati C, Baron PL, Conti G, Bresolin N, Scarpini E. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. **Neurobiology of Aging** 2004;25(9):1169-1173.
78. Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E, Cutter GR, Mariani C, Forloni G, Pettenati C, Baron PL, Conti G, Bresolin N, Scarpini E. *CCR2-64I* polymorphism and *CCR5Δ32* deletion in patients with Alzheimer's disease. **Journal of the Neurological Sciences** 2004; 225: 79-83.
79. Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, Tekin S, Lane R, Ferris S. Behavioral symptoms in mild cognitive impairment. **Neurology** 2004; 62(7): 1199-1201.
80. Giagulli C, Scarpini E, Ottoboni L, Narumiya S, Butcher EC, Constantin G, Laudanna C. RhoA and zeta PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. **Immunity** 2004; 20(1): 25-35.
81. Conti G, De Pol A, Scarpini E, Vaccina F, De Riz M, Baron P, Tiriticco M, Scarlato G. Interleukin-1 beta and interferon-gamma induce proliferation and apoptosis in cultured Schwann cells. **Journal of Neuroimmunology** 2002; 124(1-2): 29-35.
82. Scarpini E, Cogiamanian F. Alzheimer's disease: from molecular pathogenesis to innovative therapies. **Expert Reviews in Neurotherapeutics** 2003; 3(5): 619-30.
83. Guidi I, Galimberti D, Venturelli E, Lovati C, Del Bo R, Fenoglio C, Gatti A, Dominici R, Galbiati S, Virgilio R, Pomati S, Comi GP, Mariani C, Forloni G, Bresolin N, Scarpini E. Influence of the Glu298Asp polymorphism of *NOS3* on age at onset and homocysteine levels in AD patients. **Neurobiology of Aging**, 2005; 26(6): 789-794.
84. Del Bo R, Scarlato, M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, Virgilio R, Galimberti D, Galimberti G, Crimi M, Ferrarese C, Scarpini E, Bresolin N, Comi GP. VEGF gene variability is associated with increased risk of Alzheimer's disease. **Annals of Neurology**, 2005; 57: 373-78.
85. Furlan R, Rovaris M, Martinelli Boneschi F, Khademi M, Bergami A, Gironi M, Deleidi M, Agosta F, Franciotta D, Scarpini E, Uccelli A, Zaffaroni M, Kurne A, Comi G, Olsson T, Filippi M, Martino G. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. **Journal of Neuroimmunology** 2005; 165(1-2): 192-200.
86. Venturelli E, Galimberti D, Lovati C, Fenoglio C, Mariani C, Forloni G, Bresolin N, Scarpini E. The *T-786C* *NOS3* polymorphism in Alzheimer's disease: association and influence on gene expression. **Neuroscience Letters** 2005; 382: 300-303.
87. Galimberti D, Fenoglio C, Clerici R, Comi C, De Riz M, Rottoli M, Piccio L, Ronzoni M, Venturelli E, Monaco F, Poloni M, Bresolin N, Scarpini E. E-selectin *A561C* and *G98T* polymorphisms influence susceptibility and progression of Multiple Sclerosis. **Journal of Neuroimmunology** 2005;165:201-205.
88. Galimberti D, Venturelli E, Gatti A, Lovati C, Fenoglio C, Mariani C, Forloni G, Bresolin N, Scarpini E. Association of neuronal Nitric Oxide Synthase *C276T* polymorphism with Alzheimer's disease. **Journal of Neurology** 2005; 252: 985-986.
89. Scalabrini D, Galimberti D, Fenoglio C, Comi C, De Riz M, Venturelli E, Castelli L, Piccio L, Ronzoni M, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. P-selectin

- glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with Multiple Sclerosis. **Neuroscience Letters** 2005; 388: 149-152.
90. Piccio L, Rossi B, Colantonio L, Grenningloh R, Gho A, Ottoboni L, Homeister JW, Scarpini E, Martinello M, Laudanna C, D'Ambrosio D, Lowe JB, Constantin G. Efficient recruitment of lymphocytes in inflamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. **Journal of Immunology** 2005; 174(9): 5805-13.
 91. Bussini S, Meda L, Scarpini E, Clementi E, Conti G, Tiriticco M, Bresolin N, Baron P. Heparan sulphate proteoglycan induces the production of NO and TNF-alpha by murine microglia. **Immunity and Ageing** 2005; 2: 11.
 92. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer's disease. **Archives of Neurology** 2005; 62(11): 1728-33.
 93. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, Scarpini E, Bresolin N, Wharton SB, Shaw PJ, Silani V. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. **Muscle & Nerve** 2005; 32(4): 541-544.
 94. Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, Clerici R, Scarpini E, Moscato G, Iudice A, Vacca G, Orefice G, Brescia Morra V, Maimone D. Absence of cerebrospinal fluid oligoclonal bands is associated with a delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. **Journal of the Neurological Sciences** 2006; 244(1-2): 97-102.
 95. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron PL, Bresolin N, Scarpini E. Oxidative imbalance in patients with Mild Cognitive Impairment and Alzheimer's disease. **Neurobiology of Aging** 2006;27(2):262-269.
 96. Del Bo, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, Galbiati S, Virgilio R, Galimberti D, Ferrarese C, Scarpini E, Bresolin N, Comi GP. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. **Neurobiology of Aging** 2006;27(5):770.
 97. Scarpini E, Galimberti D, Guidi I, Bresolin N, Scheltens P. Progressive, isolated language disturbance: its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. **Journal of the Neurological Sciences** 2006;240:45-51.
 98. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YAL, Bresolin N, Scarpini E. Intrathecal chemokine levels in Alzheimer's disease and Frontotemporal Lobar degeneration. **Neurology** 2006; 66(1):146-147.
 99. Fenoglio C, Galimberti D, Ban M, Maranian M, Scalabrini D, Venturelli E, Piccio L, De Riz M, Yeo T, Goris A, Gray J, Bresolin N, Scarpini E, Compston A, Sawcer S. SELPLG and SELP single nucleotide polymorphisms in multiple sclerosis. **Neuroscience Letters** 2006; 394(2): 92-96.
 100. Saltini G, Dominici R, Lovati C, Cattaneo M, Michelini S, Malferrari G, Caprera A, Milanesi L, Finazzi D, Bertora P, Scarpini E, Galimberti D, Venturelli E, Musicco M, Adorni F, Mariani C, Biunno I. A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. **Neuroscience Letters** 2006;398(1-2):53-8.
 101. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. **Neurobiology of Aging** 2006; 27: 904-905.
 102. Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corrà B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E. Serum MCP-1 levels are increased in Mild Cognitive Impairment and mild Alzheimer's disease. **Neurobiology of Aging** 2006; 27: 1763-1768.

103. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E. Intrathecal chemokine synthesis in Mild Cognitive Impairment and Alzheimer's disease. **Archives of Neurology** 2006;63:538-543.
104. Scarpini E, Galimberti D, Bresolin N. Genetics and neurobiology of Frontotemporal Lobar Degeneration. **Neurological Sciences** 2006, 27 Suppl.1: S32-S34.
105. Giunta M, Rigamonti AE, Scarpini E, Galimberti D, Bonomo SM, Venturelli E, Müller EE, Cella SG. The leukocyte expression of CD36 is low in patients with Alzheimer's disease and Mild Cognitive Impairment. **Neurobiology of Aging** 2007, 28(4):515-518.
106. Venturelli E, Galimberti D, Fenoglio C, Lovati C, Finazzi D, Guidi I, Corrà B, Scalabrini D, Clerici F, Mariani C, Forloni G, Bresolin N, Scarpini E. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. **Neuroscience Letters** 2006 ; 404: 217-221.
107. Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, Quadri P, Mariani C, Albani D, Forloni G. The urokinase-type plasminogen activator polymorphism PLAUI_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level. **Neurobiology of Disease** 2007; 25(3): 609-13.
108. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. **Lancet Neurology** 2007; 6(6): 501-12.
109. Fenoglio C, Galimberti D, Piccio L, Scalabrini D, Panina P, Buonsanti C, Venturelli E, Lovati C, Baron P, Forloni G, Mariani C, Bresolin N, Scarpini E. Absence of polymorphisms in TREM-2 coding region in patients with early onset dementia. **Neuroscience letters** 2007; 411: 133-137.
110. Albani D, Batelli S, Prato F, Pesaresi M, Galimberti D, Scarpini E, Bruni A, Franceschi M, Piras MR, Confaloni A, Roiter I, Artuso V, Forloni G. Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. **Neurobiology of Aging** 2007, 28(11):1682-1688.
111. Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. IP-10 haplotypes and Multiple Sclerosis: association and correlation with clinical course. **European Journal of Neurology** 2007; 14: 162-167.
112. Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, Mariani C, Bresolin N, Scarpini E. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. **European Journal of Neurology**, 2007; 14: e3-e4.
113. Arosio B, Bergamaschini L, Galimberti L, La Porta C, Zanetti M, Calabresi C, Scarpini E, Annoni G, Vergani C. +10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution. **Mechanisms of Ageing and Development** 2007; 128(10): 553-7.
114. Galimberti D, Scarpini E, Venturelli E, Strobel A, Herterich S, Fenoglio C, Guidi I, Scalabrini D, Cortini F, Bresolin N, Lesch KP, Reif A. Association of a NOS1 promoter repeat with Alzheimer's disease. **Neurobiology of Aging** 2008; 29(9): 1359-1365.
115. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group (including Scarpini E). Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. **Lancet** 2008;371(9630):2085-92.
116. Maggi S, Noale M, Zambon A, Limongi F, Romanato G, Crepaldi G; ILSA Working Group (including Scarpini E). Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging. **Atherosclerosis** 2008; 197(2): 877-82.

117. Ferrucci R, Mameli F, Guidi I, Mrakic-Spota S, Vergari M, Marceglia S, Cogiamanian F, Barbieri S, Scarpini E, Priori A. Transcranial direct current stimulation improves recognition memory in Alzheimer disease. **Neurology** 2008; 71(7):493-8.
118. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group (including Scarpini E). The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. **Journal of Neurology** 2008; 255(9): 1315-23.
119. Poli M, Gatta LB, Lovati C, Mariani C, Galimberti D, Scarpini E, Biunno I, Musicco M, Dominici R, Albertini A, Finazzi D. Interaction between the APOE varepsilon4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease. **Neurobiology of Aging** 2008; 29(10):1494-1501.
120. Castelli L, Comi C, Chiochetti A, Nicola S, Mesturini R, Giordano M, D'Alfonso S, Cerutti E, Galimberti D, Fenoglio C, Tesser F, Yagi J, Rojo JM, Perla F, Leone M, Scarpini E, Monaco F, Dianzani U. ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. **Journal of Neuroimmunology** 2007, 186(1-2):193-198.
121. Lovati C, Galimberti D, Pomati S, Capiluppi E, Dolci A, Scapellato L, Rosa S, Mailland E, Suardelli M, Vanotti A, Clerici F, Santarato D, Panteghini M, Scarpini E, Mariani C, Bertora P. Serum folate concentrations in patients with cortical and subcortical dementia. **Neuroscience Letters** 2007; 420(3):213-216.
122. Del Bo R, Ghezzi S, Scarlato M, Albani D, Galimberti D, Lucca U, Tettamanti M, Scarpini E, Forloni G, Bresolin N, Comi GP. Role of VEGF gene variability in longevity: A lesson from the Italian population. **Neurobiology of Aging** 2008; 29(12): 1917-1922.
123. Scalabrini D, Fenoglio C, Scarpini E, De Riz M, Comi C, Venturelli E, Cortini F, Piola M, Villa C, Naldi P, Monaco F, Bresolin N, Galimberti D. Candidate gene analysis of SPARCL1 gene in patients with Multiple Sclerosis. **Neuroscience Letters** 2007; 425: 173-176.
124. Galimberti D, Fenoglio C, Comi C, Scalabrini D, De Riz M, Leone M, Venturelli E, Cortini F, Piola M, Monaco F, Bresolin N, Scarpini E. MDC/CCL22 intrathecal levels in patients with multiple sclerosis. **Multiple Sclerosis** 2008; 14: 547-549.
125. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, Bresolin N, Scarpini E. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and Frontotemporal Lobar Degeneration. **Journal of Neurology** 2008 255(4):539-44.
126. Galimberti D, Scalabrini D, Fenoglio C, De Riz M, Comi C, Venturelli E, Cortini F, Piola M, Leone M, Dianzani U, D'Alfonso S, Monaco F, Bresolin N, Scarpini E. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to multiple sclerosis. **Journal of the Neurological Sciences** 2008; 267: 86-90.
127. Venturelli E, Villa C, Scarpini E, Fenoglio C, Guidi I, Lovati C, Marcone A, Cortini F, Scalabrini D, Clerici F, Bresolin N, Mariani C, Cappa S, Galimberti D. Neuronal Nitric Oxide Synthase C276T polymorphism increases the risk for Frontotemporal Lobar Degeneration. **European Journal of Neurology** 2008; 15: 77-81.
128. Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? **Current Aging Science** 2008; 1: 30-41.
129. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M; Italian Multiple Sclerosis Study Group (including Scarpini E). MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. **Journal of Neurology, Neurosurgery and Psychiatry** 2008; 79(6): 646-51.
130. Cappellano G, Orilieri E, Comi C, Chiochetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E,

- Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U. Variations of the perforin gene in patients with multiple sclerosis. **Genes & Immunity** 2008, 9(5):438-444.
131. Reif A, Scarpini E, Venturelli E, Töpner T, Fenoglio C, Lesch KP, Galimberti D. The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia. **European Journal of Neurology** 2008;15(6):637-639.
132. Borroni B, Archetti S, Alberici A, Agosti C, Gennarelli M, Bigni B, Bonvicini C, Ferrari M, Bellelli G, Galimberti D, Scarpini E, Di Lorenzo D, Caimi L, Caltagirone C, Di Luca M, Padovani A. Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. **Neurogenetics** 2008;9(3):197-205.
133. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. **Proceedings of the National Academy of Sciences USA** 2008;105(23):8050-8054.
134. Dreses-Werringloer U, Lambert J, Vingtdoux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Fosskett KJ, Campagne F, Marambaud P. A polymorphism in CALHM1 influences Ca²⁺ homeostasis, A β levels, and Alzheimer's disease risk. **Cell** 2008; 133: 1-13.
135. Benerini Gatta L, Vitali M, Zanola A, Venturelli E, Fenoglio C, Galimberti D, Scarpini E, Finazzi D. Polymorphisms in the LOC387715/ARMS2 Putative Gene and the Risk for Alzheimer's Disease. **Dement Geriatr Cogn Disord** 2008;26(2):169-174.
136. Borroni B, Ghezzi S, Agosti C, Archetti S, Fenoglio C, Galimberti D, Scarpini E, Di Luca M, Bresolin N, Comi GP, Padovani A, Del Bo R. Preliminary Evidence that VEGF Genetic Variability Confers Susceptibility to Frontotemporal Lobar Degeneration. **Rejuvenation Research** 2008;11(4):773-780.
137. Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, Marcone A, Scalabrini D, Villa C, Clerici F, Dalla Valle E, Mariani C, Cappa S, Bresolin N, Scarpini E, Galimberti D. Novel exon 1 progranulin gene variant in Alzheimer's disease. **European Journal of Neurology** 2008, 15: 1111–1117.
138. Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J 2nd, Naismith RT, Panina-Bordignon P, Passini N, Galimberti D, Scarpini E, Colonna M, Cross AH. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. **Brain** 2008; 131(Pt 11): 3081-3091.
139. Albani D, Prato F, Fenoglio C, Batelli S, Dusi S, De Mauro S, Polito L, Lovati C, Galimberti D, Mariani C, Scarpini E, Forloni G. Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. **Journal of Human Genetics** 2008 2008;53(11-12):1029-33.
140. Galimberti D, Scarpini E. New Perspectives for the Treatment of Alzheimer's Disease. **The Open Geriatric Medicine Journal** 2008;1:33-42.
141. Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Ghidoni R, Cortini F, Scalabrini D, Gallone S, Rainero I, Mandelli A, Restelli I, Binetti G, Cappa S, Mariani C, Giordana MT, Bresolin N, Scarpini E, Galimberti D. The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. **European Journal of Neurology** 2009; 16: 37-42.
142. Hansmannel F, Lendon C, Pasquier F, Dumont J, Hannequin D, Chapuis J, Laumet G, Ayril AM, Galimberti D, Scarpini E, Campion D, Amouyel P, Lambert JC. Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease? **Neuroscience Letters** 2009;449(1):76-80.
143. Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D. Candidate gene

- analysis of selectin cluster in patients with multiple sclerosis. **Journal of Neurology** 2009;256:832–833.
144. Albani D, Batelli S, Polito L, Prato F, Pesaresi M, Gajo GB, De Angeli S, Zanardo A, Galimberti D, Scarpini E, Gallucci M, Forloni G. Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso Longeva"-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. **Age (Dordr)** 2009;31(2):155-62.
 145. Villa C, Venturelli E, Fenoglio C, Clerici F, Marcone A, Benussi L, Guidoni R, Gallone S, Cortini F, Scalabrini D, Serpente M, Binetti G, Cappa S, Mariani C, Rainero I, Bresolin N, Scarpini E, Galimberti D. CCL8/MCP-2 association analysis in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. **Journal of Neurology** 2009;256:1379–1381.
 146. Galimberti D, Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Benussi L, Cortini F, Scalabrini D, Perini L, Restelli I, Binetti G, Cappa S, Mariani C, Bresolin N, Scarpini E. MCP-1 A-2518G polymorphism: effect on susceptibility for Frontotemporal Lobar Degeneration and on cerebrospinal fluid MCP-1 levels. **Journal of Alzheimer Disease** 2009; 17: 125-133.
 147. Villa C, Venturelli E, Fenoglio C, Clerici F, Marcone A, Benussi L, Gallone S, Scalabrini D, Cortini F, Serpente M, Martinelli Boneschi F, Cappa S, Binetti G, Mariani C, Rainero I, Giordana MT, Bresolin N, Scarpini E, Galimberti D. *DCUN1D1* is a risk factor for Frontotemporal Lobar Degeneration. **European Journal of Neurology** 2009; 16: 870–873.
 148. Fenoglio C, Galimberti D, Cortini F, Kauwe JSK, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K, Piccio LM, , Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E. rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. **Journal of Alzheimer Disease**, 2009; 18(3): 603-12.
 149. Albani D, Vittori A, Batelli S, Polito L, De Mauro S, Galimberti D, Scarpini E, Lovati C, Mariani C, Forloni G. The serotonin transporter gene polymorphic element 5-HTTLPR increases sporadic parkinson's disease risk in Italy. **European Neurology**, 2009;62(2):120-3.
 150. Goumidi L, Flamant F, Lendon C, Galimberti D, Pasquier F, Scarpini E, Hannequin D, Champion D, Amouyel P, Lambert JC, Meirhaeghe A. Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. **Neurobiology of Aging**2011; 32(4): 624-30.
 151. Scarpini E, Galimberti D. Alzheimer's disease: from pathogenesis to novel therapeutic approaches. **Therapy** 2009; 6(2): 259-277.
 152. Del Bo R, Corti S, Santoro D, Ghione I, Fenoglio C, Ghezzi S, Ranieri M, Galimberti D, Mancuso M, Siciliano G, Briani C, Murri L, Scarpini E, Schymick JC, Traynor BJ, Bresolin N, Comi GP. No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. **Neurobiology of Aging** 2011; 32(6):1157-8.
 153. Albani D, Prato F, Tettamanti M, Lovati C, Galimberti D, Restelli I, Mariani C, Quadri PL, Scarpini E, Lucca U, Forloni G. The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer's Disease Related Behavioral Disturbances. **Journal of Alzheimer's Disease** 2009; 18(1): 125-30.
 154. Carecchio M, Fenoglio C, De Riz M, Guidi I, Comi C, Cortini F, Venturelli E, Restelli I, Cantoni C, Bresolin N, Monaco F, Scarpini E, Galimberti D. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnesic Mild Cognitive Impairment converted to Alzheimer's disease. **Journal of the Neurological Sciences** 2009; 287(1-2): 291-3.
 155. Farina E, Baglio F, Caffarra P, Magnani G, Scarpini E, Appollonio I, Bascelli C, Cheldi A, Nemni R, Franceschi M; Italian Group for Lewy Body Dementia and Dementias Associated to Parkinsonism, Messa G, Mantovani F, Bellotti M, Olivotto F, Alberoni M,

- Isella V, Regazzoni R, Schiatti E, Vismara C, Falautano M, Barbieri A, Restelli I, Fetoni V, Donato M, Zuffi M, Castiglioni S. Frequency and clinical features of Lewy body dementia in Italian memory clinics. **Acta Biomedica** 2009;80(1):57-64.
156. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group (including Scarpini E). Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. **Multiple Sclerosis** 2009;15(7):779-88.
157. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C; Memantine Lombardy Study Group (including Scarpini E). Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study. **Drugs & Aging** 2009;26(4):321-32.
158. Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group (including Scarpini E). Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. **Neurological Sciences** 2009;30(3):193-9.
159. Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group (including Scarpini E). Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b. **Expert Opinion Biology & Therapy** 2009;9(4):387-97.
160. De Stefano N, Filippi M, Confavreux C, Vermersch P, Simu M, Sindic C, Hupperts R, Bajenaru O, Edan G, Grimaldi L, Marginean I, Medaer R, Orefice G, Pascu I, Pelletier J, Sanders E, Scarpini E, Mancardi GL. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. **Multiple Sclerosis** 2009;15(2):238-43.
161. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. **Journal of the Neurological Sciences** 2009;283(1-2):66-8.
162. Benussi L, Ghidoni R, Galimberti D, Boccardi M, Fenoglio C, Scarpini E, Frisoni GB, Binetti G. The CST3 B haplotype is associated with frontotemporal lobar degeneration. **European Journal of Neurology** 2010;17(1):143-6.
163. Lambert JC, Heath S, Even G, Champion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, the European Alzheimer's Disease Initiative Investigators (including Scarpini E), de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. **Nature Genetics** 2009; 41(10):1094-9.
164. Gallone S, Giordana MT, Scarpini E, Rainero I, Rubino E, Fenoglio P, Galimberti D, Grifoni S, Venturelli E, Acutis PL, Peletto S, Maniaci MG, Ferrero P, Zotta M, Pinessi L. Absence of TARDBP Gene Mutations in an Italian Series of Patients with Frontotemporal Lobar Degeneration. **Dementia and Geriatric Cognitive Disorders** 2009;28(3):239-43.

165. Vitali M, Venturelli E, Galimberti D, Benerini Gatta L, Scarpini E, Finazzi D. Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease. **Journal of Neural Transmission** 2009; 116(12):1635-41.
166. Braghin E, Galimberti D, Scarpini E, Bresolin N, Baron P. Alpha1-antichymotrypsin induces TNF-alpha production and NF-kappaB activation in the murine N9 microglial cell line. **Neuroscience Letters** 2009; 467(1): 40-2.
167. Laumet G, Petitprez V, Sillaire A, Ayrat AM, Hansmanel F, Chapuis J, Hannequin D, Pasquier F, Scarpini E, Galimberti D, Lendon C, Champion D, Amouyel P, Lambert JC. A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. **Neuroscience Letters** 2010;468(1):1-2.
168. Bergamaschi L, Leone MA, Fasano ME, Guerini FR, Ferrante D, Bolognesi E, Barizzone N, Corrado L, Naldi P, Agliardi C, Dametto E, Salvetti M, Visconti A, Galimberti D, Scarpini E, Vercellino M, Bergamaschi R, Monaco F, Caputo D, Momigliano-Richiardi P, D'Alfonso S. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. **Genes & Immunity** 2010;11(2):173-80.
169. Galimberti D, Scarpini E. Treatment of Alzheimer's Disease: symptomatic and disease-modifying approaches. **Current Aging Science** 2010; 3(1): 46-56.
170. Di Maria E, Cammarata S, Parodi MI, Borghi R, Benussi L, Galli M, Galimberti D, Ghidoni R, Gonella D, Novello C, Pollero V, Perroni L, Odetti P, Scarpini E, Binetti G, Tabaton M. The H1 Haplotype of the Tau Gene (MAPT) is Associated with Mild Cognitive Impairment. **Journal of Alzheimer's Disease** 2010; 19(3): 909-14.
171. Villa C, Venturelli E, Fenoglio C, De Riz M, Scalabrini D, Cortini F, Serpente M, Cantoni C, Bresolin N, Scarpini E, Galimberti D. Candidate gene analysis of semaphorins in patients with Alzheimer's disease. **Neurological Sciences** 2010; 31:169-73.
172. De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, Venturelli E, Pietroboni A, Piola M, Naismith RT, Parks BJ, Fumagalli G, Bresolin N, Cross AH, Scarpini E. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. **Neuroscience Letters** 2010;469:234-6.
173. Comi C, Carecchio M, Chiochetti A, Nicola S, Galimberti D, Fenoglio C, Cappellano G, Monaco F, Scarpini E, Dianzani U. Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline. **Journal of Alzheimer's Disease** 2010;19(4):1143-8.
174. Galimberti D, Fenoglio C, Cortini F, Serpente M, Venturelli E, Villa C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Scalabrini D, Restelli I, Boneschi FM, Cappa S, Binetti G, Mariani C, Rainero I, Giordana MT, Bresolin N, Scarpini E. GRN variability contributes to sporadic frontotemporal lobar degeneration. **Journal of Alzheimer's Disease** 2010;19(1):171-7.
175. Cantoni C, Fenoglio C, Cortini F, Venturelli E, Villa C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Scalabrini D, Franceschi M, Cappa S, Binetti G, Mariani C, Rainero I, Giordana MT, Bresolin N, Scarpini E, Galimberti D. FUS/TLS Genetic Variability in Sporadic Frontotemporal Lobar Degeneration. **Journal of Alzheimer's Disease** 2010;19(4):1317-22.
176. Martinelli-Boneschi F, Esposito F, Scalabrini D, Fenoglio C, Rodegher ME, Brambilla P, Colombo B, Ghezzi A, Capra R, Collimedaglia L, Coniglio G, De Riz M, Serpente M, Cantoni C, Scarpini E, Martinelli V, Galimberti D, Comi G. Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. **European Journal of Neurology** 2010;17:740-5.
177. Mishto M, Bellavista E, Ligorio C, Textoris-Taube K, Santoro A, Giordano M, D'Alfonso S, Listì F, Nacmias B, Cellini E, Leone M, Grimaldi LM, Fenoglio C, Esposito F, Martinelli-Boneschi F, Galimberti D, Scarpini E, Seifert U, Amato MP, Caruso C, Foschini MP, Kloetzel PM, Franceschi C. Immunoproteasome LMP2 60HH Variant Alters MBP

- Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. **PLoS One** 2010;5(2):e9287.
178. Lovati C, Galimberti D, Albani D, Bertora P, Venturelli E, Cislighi G, Guidi I, Fenoglio C, Cortini F, Clerici F, Finazzi D, Forloni G, Scarpini E, Mariani C. APOE ϵ 2 and ϵ 4 influence the susceptibility for Alzheimer's disease but not other dementias. **International Journal of Molecular Epidemiological Genetics** 2010; 1(3): 193-200.
179. Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group (including Scarpini E). Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. **Multiple Sclerosis** 2010; 16(11): 1360-6.
180. Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. **Brain Research** 2010;28;1333:64-71.
181. Fenoglio C, Scalabrini D, Esposito F, Comi C, Cavalla P, De Riz M, Martinelli V, Piccio LM, Venturelli E, Fumagalli G, Capra R, Collimedaglia L, Ghezzi A, Rodegher ME, Vercellino M, Leone M, Giordana MT, Bresolin N, Monaco F, Comi G, Scarpini E, Martinelli-Boneschi F, Galimberti D. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. **Genes & Immunity** 2010;11(6):497-503.
182. Lescai F, Pirazzini C, D'Agostino G, Santoro A, Ghidoni R, Benussi L, Galimberti D, Federica E, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Sorbi S, Bagnoli S, Tagliavini F, Albani D, Boneschi FM, Binetti G, Forloni G, Quadri P, Scarpini E, Franceschi C. Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. **Journal of Alzheimer's Disease** 2010;21(2):385-8.
183. Galimberti D, Scarpini E. Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. **International Journal of Clinical and Experimental Medicine** 2010;3(2):129-43.
184. Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Scalabrini D, Cortini F, Fumagalli G, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration? **Neuroscience Letters** 2010;482:240-4.
185. Lambert JC, Sleegers K, González-Pérez A, Ingelsson M, Beecham GW, Hiltunen M, Combarros O, Bullido MJ, Brouwers N, Bettens K, Berr C, Pasquier F, Richard F, Dekosky ST, Hannequin D, Haines JL, Tognoni G, Fiévet N, Dartigues JF, Tzourio C, Engelborghs S, Arosio B, Coto E, De Deyn P, Del Zompo M, Mateo I, Boada M, Antunez C, Lopez-Arrieta J, Epelbaum J, Schjeide BM, Frank-Garcia A, Giedraitis V, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Delepine M, Zelenika D, Lathrop M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Valdivieso F, Vepsäläinen S, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Mann D, Marambaud P, Seripa D, Galimberti D, Tanzi RE, Bertram L, Lendon C, Lannfelt L, Licastro F, Campion D, Pericak-Vance MA, Soininen H, Van Broeckhoven C, Alperovitch A, Ruiz A, Kamboh MI, Amouyel P. The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. **Journal of Alzheimer's Disease** 2010;22(1):247-55.
186. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group(including Scarpini E). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. **New England Journal of Medicine** 2010;362(5):402-15.

187. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group (including Scarpini E). Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. **Multiple Sclerosis** 2010;16(1):68-77.
188. Borroni B, Bonvicini C, Galimberti D, Tremolizzo L, Papetti A, Archetti S, Turla M, Alberici A, Agosti C, Premi E, Appollonio I, Rainero I, Ferrarese C, Gennarelli M, Scarpini E, Padovani A. Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. **Neurobiology of Aging** 2011; 32(3): 555.e1-8.
189. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group (including Scarpini E). Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. *Neurology* 2011; 77(21): 1887-95.
190. Cortini F, Fenoglio C, Venturelli E, Villa C, Clerici F, Serpente M, Cantoni C, Fumagalli G, Mariani C, Bresolin N, Scarpini E, Galimberti D. Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer's disease. **Journal of Neurology** 2011; 258: 704-5.
191. Venturelli E, Villa C, Fenoglio C, Clerici F, Marccone A, Benussi L, Ghidoni R, Gallone S, Cortini F, Serpente M, Cantoni C, Fumagalli G, Ridolfi E, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. **Journal of Alzheimer's Disease** 2011; 23(4):701-7.
192. Galimberti D, Scarpini E. Inflammation and oxidative damage in Alzheimer's disease: friend or foe? **Frontiers in Biosciences (Schol Ed)**. 2011;3:252-66.
193. Lambert JC, Zelenika D, Hiltunen M, Chouraki V, Combarros O, Bullido MJ, Tognoni G, Fiévet N, Boland A, Arosio B, Coto E, Zompo MD, Mateo I, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Delepine M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Valdivieso F, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Lathrop M, Soininen H, Amouyel P. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. **Neurobiology of Aging** 2011; 32(4): 756.e11-5.
194. Galimberti D, Scarpini E. Alzheimer's Disease: From Pathogenesis to Disease-Modifying Approaches. **CNS Neurological Disorders Drug Targets** 2011; 10(2): 163-74.
195. Pietroboni AM, Fumagalli GG, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Carecchio M, Bassi M, Bresolin N, Galbiati D, Galimberti D, Scarpini E. Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. **Journal of Alzheimer's Disease** 2011; 24(2): 253-9.
196. Lescai F, Chiamenti AM, Codemo A, Pirazzini C, D'Agostino G, Ruaro C, Ghidoni R, Benussi L, Galimberti D, Esposito F, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Sorbi S, Tagliavini F, Albani D, Boneschi FM, Binetti G, Santoro A, Forloni G, Scarpini E, Crepaldi G, Gabelli C, Franceschi C. An APOE Haplotype Associated with Decreased $\epsilon 4$ Expression Increases the Risk of Late Onset Alzheimer's Disease. **Journal of Alzheimer's Disease** 2011; 24(2): 235-45.
197. Bollati V, Galimberti D, Pergoli L, Valle ED, Barretta F, Cortini F, Scarpini E, Bertazzi PA, Baccarelli A. DNA methylation in Repetitive Elements and Alzheimer disease. **Brain Behavior and Immunity** 2011; 25(6): 1078-83.
198. Ragheb S, Li Y, Simon K, Vanhaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. **Multiple Sclerosis** 2011; 17(7): 819-29.

199. Bergamaschi L, Ban M, Barizzone N, Leone M, Ferrante D, Fasano ME, Guerini FR, Corrado L, Naldi P, Dametto E, Agliardi C, Salvetti M, Mechelli R, Galimberti D, Scarpini E, Cavalla P, Bargiggia V, Caputo D, Cordera S, Monaco F, Momigliano-Richiardi P, D'Alfonso S. Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. **Journal of Medical Genetics** 2011; 48(7): 485-92.
200. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rütger E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wilfang J, Dichgans M, Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC; the Alzheimer's Disease Neuroimaging Initiative, van Duijn CM, Breteler MM, Ikram MA, Destefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S; CHARGE consortium, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M; EADI1 consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snædal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. **Nature Genetics** 2011; 43(5): 429-35.
201. Grünblatt E, Reif A, Jungwirth S, Galimberti D, Weber H, Scarpini E, Sauer C, Wichart I, Rainer MK, Huber K, Danielczyk W, Tragl KH, Deckert J, Fischer P, Riederer P. Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: The VITA and Milano studies. **Journal of Psychiatric Research** 2011; 45(9): 1250-6.
202. Galimberti D, Macmurray J, Scalabrini D, Fenoglio C, De Riz M, Comi C, Comings D, Cortini F, Villa C, Serpente M, Cantoni C, Ridolfi E, Fardipoor MH, Leone M, Monaco F, Bresolin N, Scarpini E. GSK3 β genetic variability in patients with Multiple Sclerosis. **Neuroscience Letters** 2011; 497(1): 46-8.
203. Villa C, Fenoglio C, De Riz M, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Cortini F, Serpente M, Cantoni C, Fumagalli G, Boneschi FM, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. **Rejuvenation Research** 2011; 14(3): 275-81.
204. Dominici R, Ronchi M, Galimberti D, Scarpini E, Finazzi D. Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease. **International Journal of Alzheimer's Disease** 2011 Apr 7;2011:576143.

205. Villa C, Ghezzi L, Pietroboni AM, Fenoglio C, Cortini F, Serpente M, Cantoni C, Ridolfi E, Marcone A, Benussi L, Ghidoni R, Jacini F, Arighi A, Fumagalli GG, Mandelli A, Binetti G, Cappa S, Bresolin N, Scarpini E, Galimberti D. A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. **Journal of Alzheimer's Disease** 2011; 26: 19-26.
206. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, Pasquier F, Dubois B, Tognoni G, Fiévet N, Brouwers N, Bettens K, Arosio B, Coto E, Del Zompo M, Mateo I, Epelbaum J, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Valdivieso F, Vepsäläinen S, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Soininen H, Dartigues JF, Kamboh MI, Van Broeckhoven C, Lambert JC, Amouyel P, Campion D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. **Molecular Psychiatry**. 2011; 16(9): 903-7.
207. Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group (including Scarpini E). Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β -1a in the COGNITIVE Impairment in MULTIPLE Sclerosis (COGIMUS) study. **BMC Neurology** 2011; 11: 125.
208. Bossu P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, Scarpini E, Spalletta G, Caltagirone C, Padovani A, Borroni B. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. **Journal of Neuroinflammation**. 2011;8(1):65.
209. Polito L, Prato F, Rodilossi S, Ateri E, Galimberti D, Scarpini E, Clerici F, Mariani C, Forloni G, Albani D. A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the Italian population do not support a large effect on Alzheimer's disease risk. **International Journal of Alzheimer's Disease** 2011;2011:312341.
210. Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer's disease. **Therapeutic Advances in Neurological Disorders** 2011; 4: 203-216.
211. Galimberti D, Scarpini E. Progress in Alzheimer's disease. **Journal of Neurology** 2012; 259(2): 201-11.
212. Serpente M, Fenoglio C, Villa C, Cortini F, Cantoni C, Ridolfi E, Clerici F, Marcone A, Benussi L, Ghidoni R, Boneschi FM, Gallone S, Cappa S, Binetti G, Franceschi M, Rainero I, Giordana MT, Mariani C, Bresolin N, Scarpini E, Galimberti D. Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. **Journal of Alzheimer's Disease** 2011; 26: 787-93.
213. Cagliani R, Fumagalli M, Guerini FR, Riva S, Galimberti D, Comi GP, Agliardi C, Scarpini E, Pozzoli U, Forni D, Caputo D, Asselta R, Biasin M, Paraboschi EM, Bresolin N, Clerici M, Sironi M. Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. **Human Genetics** 2012; 131(1): 87-97.
214. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B,

- Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. **Alzheimers & Dementia** 2011;7(4):386-395.e6.
215. Rainero I, Rubino E, Negro E, Gallone S, Galimberti D, Gentile S, Scarpini E, Pinessi L. Heterosexual Pedophilia in a Frontotemporal Dementia Patient with a Mutation in the Progranulin Gene. **Biological Psychiatry** 2011; 70(9): e43-4.
216. Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, Scarpini E. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. **Neuroscience Letters** 2011; 504(1): 9-12.
217. Cerami C, Marcone A, Galimberti D, Villa C, Scarpini E, Cappa SF. From Genotype to Phenotype: Two Cases of Genetic Frontotemporal Lobar Degeneration with Premorbid Bipolar Disorder. **Journal of Alzheimer's Disease** 2011; 27: 791-7.
218. Carecchio M, Fenoglio C, Cortini F, Comi C, Benussi L, Ghidoni R, Borroni B, De Riz M, Serpente M, Cantoni C, Franceschi M, Albertini V, Monaco F, Rainero I, Binetti G, Padovani A, Bresolin N, Scarpini E, Galimberti D. Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. **Journal of Alzheimer's Disease** 2011; 27: 781-90.
219. Mosca L, Marazzi R, Ciccone A, Santilli I, Bersano A, Sansone V, Grosso E, Mandrile G, Giachino DF, Adobbati L, Corengia E, Agostoni E, Fiumani A, Gallone S, Scarpini E, Guidotti M, Sterzi R, Ajmone C, Marocchi A, Penco S. NOTCH3 gene mutations in subjects clinically suspected of CADASIL. **Journal of the Neurological Sciences** 2011;307(1-2):144-8.
220. Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B. Cessation versus Continuation of Galantamine Treatment after 12 Months of Therapy in Patients with Alzheimer's Disease: A Randomized, Double Blind, Placebo Controlled Withdrawal Trial. **Journal of Alzheimer's Disease** 2011;26(2):211-20.
221. Rossi B, Zenaro E, Angiari S, Ottoboni L, Bach S, Piccio L, Pietronigro EC, Scarpini E, Fusco M, Leon A, Constantin G. Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. **Journal of Neuroimmunology** 2011;233(1-2):97-105.
222. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group (including Scarpini E). Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. **Lancet Neurology** 2011;10(6): 520-9.
223. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group (including Scarpini E). Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study. **Multiple Sclerosis** 2011; 17(8): 991-1001.
224. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group (including Scarpini E). Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. **Annals of Neurology** 2011; 69(1): 75-82.
225. Annunziata P, De Santi L, Di Rezze S, Millefiorini E, Capello E, Mancardi G, De Riz M, Scarpini E, Vecchio R, Patti F. Clinical features of Sjogren's syndrome in patients with multiple sclerosis. **Acta Neurologica Scandinavica** 2011;124(2):109-14.
226. Caso F, Villa C, Fenoglio C, Santangelo R, Agosta F, Coppi E, Falautano M, Comi G, Filippi M, Scarpini E, Magnani G, Galimberti D. The GRN Cys157LysfsX97 Mutation is Associated with Nonfluent Variant of Primary Progressive Aphasia Clinical Phenotype. **Journal of Alzheimer's Disease** 2012; 28: 759-63.

227. Martinelli Boneschi F, Fenoglio C, Brambilla P, Sorosina M, Giacalone G, Esposito F, Serpente M, Cantoni C, Ridolfi E, Rodegher M, Moiola L, Colombo B, De Riz M, Martinelli V, Scarpini E, Comi G, Galimberti D. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. **Neuroscience Letters** 2012; 508(1): 4-8.
228. Ghidoni R, Stoppani E, Rossi G, Piccoli E, Albertini V, Paterlini A, Glionna M, Pegoiani E, Agnati LF, Fenoglio C, Scarpini E, Galimberti D, Morbin M, Tagliavini F, Binetti G, Benussi L. Optimal Plasma Progranulin Cutoff Value for Predicting Null Progranulin Mutations in Neurodegenerative Diseases: A Multicenter Italian Study. **Neurodegenerative Diseases** 2012; 9(3):121-7.
229. Ghezzi L, Arighi A, Pietroboni AM, Jacini F, Fumagalli GG, Esposito A, Bresolin N, Galimberti D, Scarpini E. Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. **Journal of Neurology** 2012; 259(7):1470-1.
230. Musicco M, Padovani A, Sorbi S, Scarpini E, Caffarra P, Cappa S, Clerici F, Tabaton M, Caltagirone C, Bonavita V, Bruni AC, Bruno G, Federico A, Ferrarese C, Marra C, Nacmias B, Parnetti L, Pettenati C, Sorrentino G, Tagliavini F, Mariani C. Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease. **Neurological Sciences** 2012; 33(1): 201-8.
231. Guerini FR, Cagliani R, Forni D, Agliardi C, Caputo D, Cassinotti A, Galimberti D, Fenoglio C, Biasin M, Asselta R, Scarpini E, Comi GP, Bresolin N, Clerici M, Sironi M. A Functional Variant in ERAP1 Predisposes to Multiple Sclerosis. **PLoS One** 2012;7(1):e29931.
232. Galimberti D, Scarpini E. Behavioral Genetics of Neurodegenerative Disorders. **Current Topics in Behavioral Neurosciences** 2012; 12: 615–31.
233. Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, Candeletti S, Gussago C, Galimberti D, Scarpini E, Dell'Osso B, Altamura C, Maccarrone M, Bergamaschini L, D'Addario C, Mari D. Pin1 Contribution to Alzheimer's Disease: Transcriptional and Epigenetic Mechanisms in Patients with Late-Onset Alzheimer's Disease. **Neurodegenerative Diseases** 2012; 10(1-4):207-11.
234. Cagliani R, Guerini FR, Fumagalli M, Riva S, Agliardi C, Galimberti D, Pozzoli U, Goris A, Dubois B, Fenoglio C, Forni D, Sanna S, Zara I, Pitzalis M, Zoledziewska M, Cucca F, Marini F, Comi GP, Scarpini E, Bresolin N, Clerici M, Sironi M. A trans-specific polymorphism in ZC3HAV1 is maintained by long-standing balancing selection and may confer susceptibility to multiple sclerosis. **Molecular Biology and Evolution** 2012; 29(6):1599-613.
235. Di Maria E, Giorgio E, Uliana V, Bonvicini C, Faravelli F, Cammarata S, Galimberti D, Scarpini E, Zanetti O, Gennarelli M, Tabaton M. Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. **Journal of Alzheimer's Disease** 2012; 29(3):699-705.
236. D'Addario C, Dell'osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, Galimberti D, Fenoglio C, Cortini F, Scarpini E, Arosio B, Di Francesco A, Di Benedetto M, Romualdi P, Candeletti S, Mari D, Bergamaschini L, Bresolin N, Maccarrone M, Altamura AC. Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. **Neuropsychopharmacology** 2012;37(7):1647-55. doi: 10.1038/npp.2012.10. [Epub ahead of print]
237. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y, Sleegers K, Ikram MA, Hiltunen M, Reitz C, Mateo I, Feulner T, Bullido M, Galimberti D, Concaro L, Alvarez V, Sims R, Gerrish A, Chapman J, Deniz-Naranjo C, Solfrizzi V, Sorbi S, Arosio B, Spalletta G, Siciliano G, Epelbaum J, Hannequin D, Dartigues JF, Tzourio C, Berr C, Schrijvers EM, Rogers R, Tosto G, Pasquier F, Bettens K, Van Cauwenberghe C, Fratiglioni

- L, Graff C, Delepine M, Ferri R, Reynolds CA, Lannfelt L, Ingelsson M, Prince JA, Chillotti C, Pilotto A, Seripa D, Boland A, Mancuso M, Bossù P, Annoni G, Nacmias B, Bosco P, Panza F, Sanchez-Garcia F, Del Zompo M, Coto E, Owen M, O'Donovan M, Valdivieso F, Caffara P, Scarpini E, Combarros O, Buée L, Champion D, Soinen H, Breteler M, Riemenschneider M, Van Broeckhoven C, Alperovitch A, Lathrop M, Tréguët DA, Williams J, Amouyel P. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. **Molecular Psychiatry** 2012 Mar 20. doi: 10.1038/mp.2012.14. [Epub ahead of print]
238. Giunta M, Rigamonti AE, Bonomo SM, Gagliano MG, Müller EE, Scarpini E, Galimberti D, Cella SG. Estrogens need IGF-1 cooperation to exert their neuroprotective effects in postmenopausal women. **Journal of Endocrinological Investigation** 2012 Mar 22. [Epub ahead of print]
239. Albani D, Boneschi FM, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C, Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G. Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. **Journal of Alzheimer's Disease** 2012; 30(4):745-9.
240. Galimberti D, Dell'Osso B, Fenoglio C, Villa C, Cortini F, Serpente M, Kittel-Schneider S, Weigl J, Neuner M, Volkert J, Leonhard C, Olmes DG, Kopf J, Cantoni C, Ridolfi E, Palazzo C, Ghezzi L, Bresolin N, Altamura AC, Scarpini E, Reif A. Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. **PLoS One** 2012;7(4):e32164.
241. Galimberti D, Scarpini E. Clinical phenotypes and genetic biomarkers of FTLD. **Journal of Neural Transmission** 2012; 119(7):851-60.
242. Galimberti D, Scarpini E. Genetics of frontotemporal lobar degeneration. **Frontiers in Neurology** 2012;3:52.
243. Cerami C, Scarpini E, Cappa SF, Galimberti D. Frontotemporal lobar degeneration: current knowledge and future challenges. **Journal of Neurology** 2012; 259: 2278-86.
244. Arighi A, Fumagalli GG, Jacini F, Fenoglio C, Ghezzi L, Pietroboni AM, De Riz M, Serpente M, Ridolfi E, Bonsi R, Bresolin N, Scarpini E, Galimberti D. Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. **Journal of Alzheimer's Disease** 2012; 31(2):447-52.
245. Crimella C, Baschiroto C, Arnoldi A, Tonelli A, Tenderini E, Airolidi G, Martinuzzi A, Trabacca A, Losito L, Scarlato M, Benedetti S, Scarpini E, Spinicci G, Bresolin N, Bassi MT. Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2. **Clinical Genetics** 2012; 82(2): 157-64.
246. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C, Lugaresi A, Merelli E, Meucci G, Motti L, Tola MR, Scarpini E, Repice AM, Massacesi L, Saccardi R; Italian BMT Study Group. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. **Multiple Sclerosis** 2012; 18(6): 835-42.
247. Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group (including Scarpini E). Patient adherence to and tolerability of self-administered interferon β -1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. **BMC Neurology** 2012; 12: 7.
248. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group (including Scarpini E). Placebo-controlled trial of oral laquinimod for multiple sclerosis. **New England Journal Medicine** 2012; 366(11): 1000-9.

249. Boggio PS, Ferrucci R, Mameli F, Martins D, Martins O, Vergari M, Tadini L, Scarpini E, Fregni F, Priori A. Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease. **Brain Stimulation** 2012; 5(3): 223-30.
250. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wiegers RL, Vellas B, Kamphuis PJ. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. **Journal of Alzheimer's Disease** 2012;31(1):225-36.
251. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C; Memantine Lombardy Study Group (including Scarpini E). Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. **Neurological Sciences** 2012; 33(1): 23-31.
252. Villa C, Ghezzi L, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Serpente M, Cantoni C, Ridolfi E, Bonsi R, Cerami C, Cappa S, Binetti G, Franceschi M, Rainero I, Mariani C, Bresolin N, Scarpini E, Galimberti D. Genetics and Expression Analysis of the Specificity Protein 4 Gene (SP4) in Patients with Alzheimer's Disease and Frontotemporal Lobar Degeneration. **Journal of Alzheimer's Disease** 2012; 31(3):537-42.
253. Polito L, Kehoe PG, Davin A, Benussi L, Ghidoni R, Binetti G, Quadri P, Lucca U, Tettamanti M, Clerici F, Bagnoli S, Galimberti D, Nacmias B, Sorbi S, Guaita A, Scarpini E, Mariani C, Forloni G, Albani D. The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. **Alzheimers & Dementia** 2013;9(4):392-9.
254. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'osso B, Bari M, Galimberti D, Scarpini E, Altamura AC, Mari D, Maccarrone M. Epigenetic regulation of Fatty Acid amide hydrolase in Alzheimer disease. **PLoS One** 2012;7(6):e39186.
255. Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, Gentile S, Bruni AC, St George-Hyslop PH, Scarpini E, Gallone S, Pinessi L; For the TODDEM Study Group. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **Neurology** 2012; 79(15): 1556-1562.
256. Galimberti D, Scarpini E. Progress in multiple sclerosis research in the last year. **Journal of Neurology** 2012; 259(7):1497-501.
257. D'Addario C, Dell'osso B, Galimberti D, Palazzo MC, Benatti B, Di Francesco A, Scarpini E, Altamura AC, Maccarrone M. Epigenetic Modulation of BDNF Gene in Patients with Major Depressive Disorder. **Biological Psychiatry** 2013; 15;73(2):e6-7.
258. Galimberti D, D'Addario C, Dell'Osso B, Fenoglio C, Marcone A, Cerami C, Cappa SF, Palazzo MC, Arosio B, Mari D, Maccarrone M, Bresolin N, Altamura AC, Scarpini E. Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. **Neurological Sciences** 2013;34(6):899-903.
259. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y, Sleegers K, Ikram MA, Hiltunen M, Reitz C, Mateo I, Feulner T, Bullido M, Galimberti D, Concari L, Alvarez V, Sims R, Gerrish A, Chapman J, Deniz-Naranjo C, Solfrizzi V, Sorbi S, Arosio B, Spalletta G, Siciliano G, Epelbaum J, Hannequin D, Dartigues JF, Tzourio C, Berr C, Schrijvers EM, Rogers R, Tosto G, Pasquier F, Bettens K, Van Cauwenberghe C, Fratiglioni L, Graff C, Delepine M, Ferri R, Reynolds CA, Lannfelt L, Ingelsson M, Prince JA, Chillotti C, Pilotto A, Seripa D, Boland A, Mancuso M, Bossù P, Annoni G, Nacmias B, Bosco P, Panza F, Sanchez-Garcia F, Zompo MD, Coto E, Owen M, O'Donovan M, Valdivieso F, Caffara P, Scarpini E, Combarros O, Buée L, Champion D, Soininen H, Breteler M, Riemenschneider M, Van Broeckhoven C, Alperovitch A, Lathrop M, Trégouët DA, Williams J, Amouyel P. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. **Molecular Psychiatry** 2012 Sep 18. doi: 10.1038/mp.2012.75. [Epub ahead of print]

260. Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L, Galimberti D, Guerini F, Barizzone N, Perla F, Leone M, D'Alfonso S, Caputo D, Scarpini E, Cantello R, Dianzani U. The impact of osteopontin gene variations on multiple sclerosis development and progression. **Clinical and Developmental Immunology** 2012;2012:212893.
261. iloca C, Ticozzi N, Pensato V, Corrado L, Del Bo R, Bertolin C, Fenoglio C, Gagliardi S, Calini D, Lauria G, Castellotti B, Bagarotti A, Corti S, Galimberti D, Cagnin A, Gabelli C, Ranieri M, Ceroni M, Siciliano G, Mazzini L, Cereda C, Scarpini E, Sorarù G, Comi GP, D'Alfonso S, Gellera C, Ratti A, Landers JE, Silani V; SLAGEN Consortium. Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. **Neurobiology of Aging** 2012 Oct 11. pii: S0197-4580(12)00473-3.
262. Ghezzi L, Scarpini E, Rango M, Arighi A, Bassi MT, Tenderini E, De Riz M, Jacini F, Fumagalli GG, Pietroboni AM, Galimberti D, Bresolin N. A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val EIF2B3 mutation. **Neurology** 2012; 79(20):2077-8.
263. Clerici F, Caracciolo B, Cova I, Fusari Imperatori S, Maggiore L, Galimberti D, Scarpini E, Mariani C, Fratiglioni L. Does Vascular Burden Contribute to the Progression of Mild Cognitive Impairment to Dementia?. **Dementia and Geriatric Cognitive Disorders** 2012;34(3-4):235-243.
264. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis. **International Journal of Molecular Science** 2012;13(10):13227-39.
265. Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. **Journal of the Neurological Sciences** 2013 Jan 5. doi:pii: S0022-510X(12)00637-5. 10.1016/j.jns.2012.12.013. [Epub ahead of print].
266. Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, Santangelo R, Brambilla P, Esposito F, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Confaloni A, Bruno G, Pichler S, Mayhaus M, Riemenschneider M, Mariani C, Comi G, Scarpini E, Binetti G, Forloni G, Franceschi M, Albani D. Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. **Neurobiology of Aging** 2013; 34(6):1711.e7-13.
267. Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G; The MS Study Group-Italian Society of Neurology. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. **Neurological Sciences** 2013 Jan 25. [Epub ahead of print]
268. Ridolfi E, Fenoglio C, Cantoni C, Calvi A, De Riz M, Pietroboni A, Villa C, Serpente M, Bonsi R, Vercellino M, Cavalla P, Galimberti D, Scarpini E. Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. **International Journal of Molecular Science** 2013;14(3):4375-84.
269. Cerami C, Marcone A, Galimberti D, Zamboni M, Fenoglio C, Serpente M, Scarpini E, Cappa SF. Novel Evidence of Phenotypical Variability in the Hexanucleotide Repeat Expansion in Chromosome 9. **Journal of Alzheimer's Disease** 2013; 35(3): 455-62.
270. Villa C, Ridolfi E, Fenoglio C, Ghezzi L, Vimercati R, Clerici F, Marcone A, Gallone S, Serpente M, Cantoni C, Bonsi R, Cioffi S, Cappa S, Franceschi M, Rainero I, Mariani C, Scarpini E, Galimberti D. Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease. **Journal of Alzheimer's Disease** 2013 Feb 22. [Epub ahead of print]
271. Piscopo P, Rivabene R, Galimberti D, Crestini A, Talarico G, Vanacore N, Scarpini E, Bruno G, Confaloni A. Gender Effects on Plasma PGRN Levels in Patients with

- Alzheimer's Disease: A Preliminary Study. **Journal of Alzheimer's Disease** 2013; 35(2): 313-8.
272. Arosio B, Abbate C, Galimberti D, Rossi PD, Inglese S, Fenoglio C, Ridolfi E, Gussago C, Casati M, Tedone E, Ferri E, Serpente M, Scarpini E, Mari D. GRN Thr272fs Clinical Heterogeneity: A Case with Atypical Late Onset Presenting with a Dementia with Lewy Bodies Phenotype. **Journal of Alzheimer's Disease** 2013;35(4):669-74.
273. Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi R, Arighi A, Fumagalli GG, Del Bo R, Bruni AC, Anfossi M, Clodomiro A, Cupidi C, Nacmias B, Sorbi S, Piaceri I, Bagnoli S, Bessi V, Marcone A, Cerami C, Cappa SF, Filippi M, Agosta F, Magnani G, Comi G, Franceschi M, Rainero I, Giordana M, Rubino E, Ferrero P, Rogava E, Xi Z, Confaloni A, Piscopo P, Bruno G, Talarico G, Cagnin A, Clerici F, Dell'Osso B, Comi GP, Altamura AC, Mariani C, Scarpini E. Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. **Biological Psychiatry** 2013 74: 384-91.
274. Cerami C, Marcone A, Galimberti D, Villa C, Fenoglio C, Scarpini E, Cappa SF. Novel Missense Progranulin Gene Mutation Associated with the Semantic Variant of Primary Progressive Aphasia. **Journal of Alzheimer's Disease** 2013;36(3):415-20.
275. Galimberti D, Scarpini E. Progress in Alzheimer's disease research in the last year. **Journal of Neurology** 2013; 260(7):1936-41.
276. Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy. **American Journal of Epidemiology** 2013 Jul 17. [Epub ahead of print]
277. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. An Emerging Role for Long Non-Coding RNA Dysregulation in Neurological Disorders. **International Journal of Molecular Science** 2013; 14(10): 20427-42.
278. Galimberti D, Arosio B, Fenoglio C, Serpente M, Cioffi SM, Bonsi R, Rossi P, Abbate C, Mari D, Scarpini E. Incomplete Penetrance of the C9ORF72 Hexanucleotide Repeat Expansions: Frequency in a Cohort of Geriatric Non-Demented Subjects. **Journal of Alzheimer's Disease** 2013 Oct 10. [Epub ahead of print]
279. Carecchio M, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Comi C, Terazzi E, Cantello R. Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonism. **Journal of Alzheimer's Disease** 2013 Sep 24. [Epub ahead of print]
280. Galimberti D, Scarpini E. Dementia: not only Alzheimer's disease, an eye on frontotemporal dementia. **Acta Medica Portuguesa** 2013;26(4):299-300.
281. Ridolfi E, Barone C, Scarpini E, Galimberti D. The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. **Clinical and Developmental Immunology** 2013;2013:939786.
282. Grande G, Vanacore N, Maggiore L, Cucumo V, Ghiretti R, Galimberti D, Scarpini E, Mariani C, Clerici F. Physical Activity Reduces the Risk of Dementia in Mild Cognitive Impairment Subjects: A Cohort Study. **Journal of Alzheimer's Disease** 2013 Dec 2. [Epub ahead of print]
283. Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. **Multiple Sclerosis** 2013; 19(14): 1938-42.
284. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA,

- Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Champion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F; European Alzheimer's Disease Initiative (EADI, including Scarpini E); Genetic and Environmental Risk in Alzheimer's Disease (GERAD); Alzheimer's Disease Genetic Consortium (ADGC); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvin V, Seshadri S, Williams J, Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. **Nature Genetics** 2013; 45(12): 1452-8.
285. Pietroboni A, Arighi A, Deriz M, Scarpini E, Galimberti D, Bresolin N, Rango M. Brain temperature in multiple sclerosis. **Multiple Sclerosis** 2013 Oct 24. [Epub ahead of print]
286. Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C, Gennarelli M, Turla M, Scarpini E, Sorbi S, Padovani A. Heterozygous TREM2 mutations in frontotemporal dementia. **Neurobiology of Aging** 2013 Oct 16. doi:pil: S0197-4580(13)00419-3. 10.1016/j.neurobiolaging.2013.09.017. [Epub ahead of print]
287. Galimberti D, Arosio B, Fenoglio C, Serpente M, Cioffi SM, Bonsi R, Rossi P, Abbate C, Mari D, Scarpini E. Incomplete Penetrance of the C9ORF72 Hexanucleotide Repeat Expansions: Frequency in a Cohort of Geriatric Non-Demented Subjects. **Journal of Alzheimer's Disease** 2013 Oct 10. [Epub ahead of print]
288. Calvi A, De Riz M, Pietroboni AM, Ghezzi L, Maltese V, Arighi A, Fumagalli GG, Jacini F, Donelli C, Comi G, Galimberti D, Scarpini E. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. **Immunotherapy** 2014; 6(1): 23-8.
289. Galimberti D, Reif A, Dell'osso B, Palazzo C, Villa C, Fenoglio C, Kittel-Schneider S, Leonhard C, Olmes DG, Serpente M, Paoli RA, Altamura AC, Scarpini E. C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. **Bipolar Disorders** 2013 Dec 16. doi: 10.1111/bdi.12169. [Epub ahead of print]
290. Ferrucci R, Vergari M, Cogiamanian F, Bocci T, Ciocca M, Tomasini E, De Riz M, Scarpini E, Priori A. Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis. **NeuroRehabilitation**. 2013 Nov 27. [Epub ahead of print]

291. Sorosina M, Brambilla P, Clarelli F, Barizzone N, Lupoli S, Guaschino C, Osiceanu AM, Moiola L, Ghezzi A, Coniglio G, Patti F, Mancardi G, Manunta P, Glorioso N, Guerini FR, Bergamaschi R, Perla F; PROGRESSO; PROGEMUS (including [Scarpini E](#)), Martinelli V, Cusi D, Leone M, Comi G, D'Alfonso S, Martinelli-Boneschi F. Genetic burden of common variants in progressive and bout-onset multiple sclerosis. **Multiple Sclerosis** 2013 Nov 28. [Epub ahead of print]
292. Angiari S, Rossi B, Piccio L, Zinselmeier BH, Budui S, Zenaro E, Della Bianca V, Bach SD, [Scarpini E](#), Bolomini-Vittori M, Piacentino G, Dusi S, Laudanna C, Cross AH, Miller MJ, Constantin G. Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph Nodes through P-Selectin Glycoprotein Ligand-1. **Journal of Immunology** 2013; 191(11): 5489-500.
293. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group (Including [Scarpini E](#)). Subcutaneous interferon β -1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. **PLoS One** 2013; 8(8): e74111.
294. Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; on behalf of the ALLEGRO Study Group (including [Scarpini E](#)). Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. **Journal of Neurology, Neurosurgery & Psychiatry** 2013 Sep 12. doi: 10.1136/jnnp-2013-306132. [Epub ahead of print]
295. Ross J, Sharma S, Winston J, Nunez M, Bottini G, Franceschi M, [Scarpini E](#), Frigerio E, Fiorentini F, Fernandez M, Sivilia S, Giardino L, Calza L, Norris D, Cicirello H, Casula D, Imbimbo BP. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. **Current Alzheimer Research** 2013; 10(7): 742-53.
296. Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, [Scarpini E](#), Mavilio D, Mannino S. Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. **American Journal of Epidemiology** 2013; 178(7): 1139-45.
297. Scheltens P, Twisk JW, Blesa R, [Scarpini E](#), von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. **Journal of Alzheimer's Disease** 2012; 31(1): 225-36.
298. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA; Alzheimer's Association QC Program Work Group (including [Scarpini E](#)). CSF biomarker variability in the Alzheimer's Association quality control program. **Alzheimer's & Dementia** 2013; 9(3): 251-61.
299. Ghezzi L, [Scarpini E](#), Galimberti D. Disease-modifying drugs in Alzheimer's disease. **Drug Design Development Therapy** 2013; 7: 1471-9.

CAPITOLI IN VOLUMI INTERNAZIONALI

1. Scarpini E, Galimberti D. Chemokines and their receptors in multiple sclerosis: from the role in the pathogenesis to the targeting for future treatments. In: **“Treatment and Management of Multiple Sclerosis Research”** 2005: 89-105. Novapublishers, New York, USA (Editor: Frank Columbus).
2. Galimberti D, Fenoglio C, Scarpini E. Immunological Aspects in Neurodegenerative Disorders. In: **“Neuroimmunology Research Focus”** 2007: 5-42. Novapublishers, New York, USA (Editor: Paulo V. Broglio).
3. Galimberti D, Scarpini E. Role of chemokines in neurodegeneration. In: **“Progress in chemokine research”** 2007: 141-147. Novapublishers, New York, USA (Editor: WP Linkes).
4. Galimberti D, Fenoglio C, Scarpini E. Early onset dementia: role of genetics in the pathogenesis of Alzheimer’s disease and Frontotemporal Lobar Degeneration. In: **“Alzheimer Disease in the Middle-Aged”**, 2008: 329-245. Novapublishers, New York, USA (Editor: Hyun Sil Jeong)
5. Galimberti D, Fenoglio C, Scarpini E. Alzheimer’s disease: from pathogenesis to new perspectives for treatment. In: **“A Multidisciplinary Approach to Dissect the Alzheimer’s Pathology”** 2008: 111-129. Transworld Research Network, 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India (Editors: Roberto Dominici and Ida Biunno)
6. Galimberti D, Fenoglio C, Scarpini E. Novel Therapies for Alzheimer's Disease: Potentially Disease Modifying Drugs. In: **“Cognitive Impairment: causes, diagnosis and treatments”**, 2009: 73-96, Novapublishers, New York, USA (Editor: Melanie L. Landow).
7. Fenoglio C, Scarpini E, Galimberti D. Gender-related genetic and biochemical differences: influence on susceptibility and course of multiple sclerosis. In: **“Women and Multiple Sclerosis”** 2009: 95-109, Novapublishers, New York, USA (Editor: Duane O’Mahoni and Anrai de Burca).
8. Galimberti D, Fenoglio C, Scarpini E. Genetics and Molecular Biology of Alzheimer’s disease and Frontotemporal Lobar Degeneration: analogies and differences. In: **“Neurodegeneration: theory, disorders and treatment”** 2011: 173-88. Novapublisher, New York, USA (Editor: Alexander S. McNeill).
9. Galimberti D, Scarpini E. Behavioural genetics of neurodegenerative disorders. In: **“Behavioural Neurogenetics”** 2012: 615-631. Springer-Verlag, Berlin Heidelberg (Editors: John F. Cryan and Andreas Reif).
- 10.

Abstracts pubblicati su riviste indicizzate: >400

H-index (ISI)=34

CLINICAL TRIALS PROSPETTICI (MULTICENTRICI-RANDOMIZZATI)

Dimensione Ricerca, prot. DR 01-03-05

Evoluzione della disabilità e monitoraggio concomitante della componente infiammatoria (assetto citochinico) in pazienti con sclerosi multipla secondariamente progressiva, trattati con azatioprina o placebo e con interferone (A.SP.I.R.E.). Studio in doppio cieco, randomizzato, multicentrico, pilota;

Studio Schering – prot. DR04-07-02

Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with relapsing remitting multiple sclerosis in treatment with interferon-beta-(ARIANNA) – Multicenter, randomised, double blind, placebo controlled, parallel-group-study;

Teva Pharmaceutical Industries, prot. N. LAQ/5063

An active extension of LAQ/5062 study – multinational, multi-center, randomised, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3mg and 0.6mg) of laquinimod, orally administered in relapsing-remitting (R-R) multiple sclerosis (MS) subjects;

FORTE – GA/9016

A multinational, multicenter, randomized, parallel-group, double-blind study, to compare the efficacy, tolerability and safety of glatiramer acetate injection 40mg/ml to that of glatiramer acetate injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (R-R) multiple sclerosis (MS);

Sanofi, prot. ACT10019

AVE625 A double blind placebo-controlled study of the activity of AVE 1625 at doses of 10 mg and 40 mg for 12 weeks in patients with mild to moderate Alzheimer's diseases;

Glaxo, prot. AVA102672

Studio di 54 settimane, randomizzato, in doppio cieco, controllato con placebo, a gruppi paralleli, mirato a valutare gli effetti di rosiglitazone (comprese a rilascio prolungato) come terapia aggiuntiva a donepezil sulle funzioni cognitive e sulla risposta clinica globale, in soggetti stratificati secondo il genotipo APOE 4, con malattia di Alzheimer di grado lieve-moderato (REFLECT-2);

Glaxo, prot. AVA102675

A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4);

Novartis, prot. CENA 713D2340

A 48-week, multicenter, double-blind, parallel-group evaluation of the comparative efficacy, safety and tolerability of Exelon 10 and 15 cm² patch in patients with Alzheimer's disease showing cognitive decline during an initial open-label treatment phase;

Merck Serono prot. 701048-525

Multicenter. Open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject **Rebif** New Formulation (RNF) **In a multi-dose cartridge** – **BRIDGE**;

Roche, prot. WN22018

Studio multicentrico, a dosaggio differenziato, randomizzato, in doppio cieco, a gruppi paralleli, controllato verso placebo di RO5313534 quale aggiunta al trattamento con donepezil in pazienti affetti da malattia di Alzheimer con sintomatologia da lieve a moderata;

Eli Lilly, prot. H8A-MC-LZAN

Effect of passive immunization on the progression of Alzheimer's disease: LY2062430 versus placebo;

Eli Lilly, prot. H6L-MC-LFBC

Effect of LY450139, a g-secretase inhibitor, on the progression of Alzheimer's disease as compared with placebo;

Lundbeck, prot. 12936A

Randomised, double blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with moderate Alzheimer's disease treated with donepezil;

Glaxo, prot. AZ3110866.

A fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer's disease;

Danone, prot. Alz.1.C/D

A randomised controlled trial to assess the efficacy of a food for special medical purposes (FSMP) in patients with mild Alzheimer's disease – Souvenir II trial – Danone, prot. Alz.1.C/D;

Glaxo Smith-Kleine, prot. LPZ114458

A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer's disease (LPZ114458);

Sanofi-Aventis, prot DRI10734

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5mg/die for 24 weeks in patients with mild to moderate Alzheimer's disease;

Chiesi, prot. CCD-1014-PR-0053

A randomized, placebo-controlled, multicenter study to evaluate the safety and tolerability of multiple dose regimens of CHF 5074 (200, 400, 600 mg/day for up to 12 weeks) and to explore the effects on potential markers of clinical efficacy in patients with mild cognitive impairment;

Merck Serono, prot. MK-8931-017-00

Randomised, placebo-controlled, parallel-group, double blind, efficacy and safety trial of MK-8931 in subject with mild to moderate Alzheimer's disease;

Roche, prot. WN25203C

Multicenter, randomized, double-blind, placebo-controlled, parallel-group, two years study to evaluate the effect of subcutaneous RO4909832 on cognition and function in prodromal Alzheimer's disease;

Eli-Lilly, prot. H8A-MC-LZAO

Study H8A-MC-LZAO multicenter, open-label, phase 3 study of solanezumab for 24 months in approximately 1275 patients with Alzheimer's disease;

Biogen, prot. 101MS326

A multicenter, randomized, double-blind, placebo-controlled study of the efficacy of natalizumab on reducing progression in subjects with Secondary Progressive Multiple Sclerosis;

Servier, prot. CL2-38093-012

Efficacy and safety of three doses of S38093 (2, 5 and 20 mg/die) versus placebo, in co-administration with donepezil (10 mg/die) in patient with moderate Alzheimer's disease. A twenty-four week international, multi-center, randomized, double-blind, placebo-controlled, phase 2B study;

Teva, prot. Posidonia

Studio osservazionale, della durata di 12 mesi, prospettico, che valuta l'impatto del trattamento con DMT sui disturbi dell'umore nei pazienti che hanno ricevuto una diagnosi recente di Sclerosi Multipla;

Avonex prot. AC-058B301/302

Multicenter, randomised, double-blind, parallel-group, active-controlled, group-sequential, superiority study to compare the efficacy and safety of Ponesimod to Interferon Beta-1A in patient with Relapsing-Remitting Multiple Sclerosis;

Novartis, prot. CAD106A2203

A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following repeated i.m. injections of adjuvanted CAD106;

Novartis, prot. CENA 713D2340

A 48-week, multicenter, double-blind, parallel-group evaluation of the comparative efficacy, safety and tolerability of Exelon 10 and 15 cm² patch in patients with Alzheimer's disease showing cognitive decline during an initial open-label treatment phase. Novartis, ENA713 Exelon Patch Rivastigmine, amendment to Clinical Trial Protocol CENA 713D2340;

Novartis, prot. CFTY720D2302

FTY 720 Studio multicentrico, in doppio cieco, a gruppi paralleli, della durata di 12 mesi, per confrontare l'efficacia e la sicurezza di fingolimod (FTY720) 0,5 mg e 1,25 mg, somministrato una volta al giorno per via orale versus interferone Beta-1b (Avonex), somministrato i.m. una volta alla settimana in pazienti con sclerosi multipla recidivante-remittente;

Novartis, prot. CFTY720D2306

A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 1.25 mg FTY720 administered orally once daily versus placebo in patients with Primary Progressive Multiple Sclerosis.

Novartis, prot. CFTY720D2399

Studio multicentrico, in aperto, a un solo gruppo di trattamento, per valutare la sicurezza e la tollerabilità a lungo termine di 0.5 mg di Fingolimod (FTY720) somministrato per via orale una volta al giorno in pazienti con forme Recidivanti di Sclerosi Multipla;

Novartis, prot. CFTY720DIT01

Studio pilota della durata di 18 mesi, in aperto, con il valutatore in condizioni di cecità, randomizzato, multicentrico, con controllo attivo, a gruppi paralleli, per valutare l'efficacia e la sicurezza di fingolimod a confronto con interferone beta 1b nel trattamento dei sintomi cognitivi associati alla Sclerosi Multipla Recidivante-Remittente e per valutare la possibile relazione di tali effetti con l'atrofia cerebrale regionale;

Novartis, prot. CFTY720DIT02

Studio multicentrico, randomizzato, verso controllo attivo, in aperto, della durata di 6 mesi, per valutare gli esiti riportati dai pazienti, la sicurezza e la tollerabilità di Fingolimod (FTY720) 0.5 mg/die in pazienti con Sclerosi Multipla Recidivante Remittente, candidati ad una valutazione di terapia rispetto alla precedente (DMT);

Novartis, prot. CFTY720DIT03

Studio in aperto, multicentrico, di accesso allargato, a Fingolimod (FTY720) in pazienti con Sclerosi Multipla Recidivante-Remittente, per i quali non esiste un'adeguata alternativa terapeutica;

RICERCHE MULTICENTRICHE

Quality Assessment In MS therapy – QUASIMS - Studio internazionale, in aperto, retrospettivo, multicentrico, comparativo sull'efficacia e tollerabilità della terapia con interferone beta nel trattamento della sclerosi multipla con forma a ricadute e remissioni. Biogen

A 90 weeks multi-center, randomized, double blind placebo-controlled study in patients with mild AD to investigate the safety, tolerability and Abeta-specific antibody response following injections of adjuvant

Studio osservazionale, prospettico, multicentrico, per la valutazione comparativa delle funzioni cognitive in pazienti con Sclerosi Multipla Relapsing-Remitting in trattamento con IFN-beta. (Studi Cog.I.Mu.S – Cognitive Impairment in multiple sclerosis) – Fondazione Biomedica Europea Onlus

Betaferon treatment and Exercise data Gathering IN early MS – BEGIN – Observational plan, Schering

TYSABRI Observational Program – TOP – Biogen Idec

LETTURE E RELAZIONI SU INVITO A CONGRESSI NAZIONALI ED INTERNAZIONALI

Inviti più significativi dal 2002 ad oggi:

“Il dolore neuropatico” - XXXIII Congresso della Società Italiana di Neurologia, Ottobre, 2002, Napoli.

“Treatment of Alzheimer's disease” - XII Meeting of the European Neurological Society, June 22-26, 2002, Berlin, Germany.

“Lo Studio Exceed” - Simposio Novartis, XXXIV Congresso della Società Italiana di Neurologia, 11-15 Ottobre, 2003, Roma.

“La malattia di Alzheimer: nuovi approcci terapeutici” - XXXIV Congresso della Società Italiana di Neurologia, 11-15 Ottobre, 2003, Roma.

“Dementia update: the treatment of MCI and AD” - Teaching course, XIV Meeting of the European Neurological Society, June 26-30, 2004, Barcelona, Spain.

VIII International Montreal/ Springfield Symposium on Advances in Alzheimer Therapy. April 14-17, 2004.

“Nuovi approcci terapeutici per la malattia di Alzheimer”, 22 Settembre 2004, Aggiornamenti IRCCS Istituto Auxologico, Milano.

“La Demenza Vascolare: diagnostica differenziale e gestione del paziente”. Corso Residenziale Pfizer Neuroscience, Milano, 13 e 27 maggio 2004.

“Inquadramento nosografico delle malattie demielinizzanti del SNC”. Corso Biennale su Malattie Demielinizzanti, 3 Marzo 2004, Milano.

“Meccanismo molecolare di migrazione linfocitaria nel SNC”. 2° Congresso Nazionale Soc. It. Citom. Clin. Sper. 31 Marzo 2004, Torino.

“La malattia di Alzheimer” Aggiornamenti in Neurologia, 15 Gennaio 2004, San Pio X, Milano.

Alzheimer’s Disease Expert Input Forum, May 13, 2005, Frankfurt, Germany - Expert for Italy.

“Storia naturale della sclerosi multipla”. Corso Biennale su Malattie Demielinizzanti, 2 Marzo 2005, Milano.

Educational Forum for the Diagnosis and Treatment of Alzheimer’s Disease with Cerebrovascular Disease. February, 18-19, 2005, Berlin, Germany – Italian opinion leader.

“Discussione e commento sulla terapia di un caso clinico di SM”. Approfondimenti monotematici sulla SM. 17-18 Marzo 2005, Gallarate.

“Fattori genetici ed immunologici di suscettibilità alla sclerosi multipla”. Giornate di Medicina Molecolare IRCCS Fondazioni Don Gnocchi 6 Aprile 2005, Milano.

“Meccanismi di reclutamento linfocitario attraverso la barriera ematoencefalica nelle malattie infiammatorie del SNC”. 1 Aprile 2005, Università A. Avogadro, Novara.

Exelon InDDEx Data Review Meeting. April 11, 2005. Miami, USA. Member of the Steering Committee.

“Inflammation and Alzheimer’s disease: genetic aspects” - 41st Annual Meeting of the Italian Association of Neuropathology (AINP) jointly with the French Society of Neuropathology – 31st Meeting of the Italian Association for Research on Brain Aging (AIRIC), May 26-28, 2005, Saluzzo, Italy.

Teaching Course on “Treatment of Alzheimer’s disease” - XVI Meeting of the European Neurological Society, May 27-31, 2006 Lausanne, Switzerland

“Demenza e Sclerosi Multipla” Congresso della Società di Neurogeriatria, 18 dicembre 2006, Milano

- XVII Meeting of the European Neurological Society - “Behavioural disorders in Neurology” Plenary Symposium at the XVI Meeting of the European Neurological Society, June 2007, Rhodes, Greece

- XVIII Meeting of the European Neurological Society Symposium “Behavioural disorders and dementia”- titolo dell’intervento: “Behavioural disturbances in frontotemporal lobar degeneration: recent advances in molecular genetics and neurobiology” – Nice, June 7-11, 2008

- 19th Meeting of the European Neurological Society - Teaching course on “Diagnosis and treatment of dementia” – Title: “Treatment of dementias: facts and perspectives”, Milan, June 20-24, 2009.

- 20th Meeting of the European Neurological Society - Teaching course on “Dementia” – Title: “Biological bases of new treatments for Alzheimer’s disease” – Berlin, Germany, June 19-23, 2010

- XIV Meeting of the European neurological Society, Geneva, Switzerland, September 25-28, 2010 – Teaching course on “Dementia” – Title: “Anticholinesterases: more of the same?”

- Meeting “A tribute to R. Lisak”, Detroit, USA, May 18, 2012 – Title: “Immunotherapy of Alzheimer’s disease”

- 16th Congress of the European-Federation-of-Neurological-Societies (EFNS) - Stockholm, Sweden, September 08-11, 2012 - Title: “Standard pharmacotherapy of AD: do's and dont's”

CHAIRMAN A CONGRESSI NAZIONALI ED INTERNAZIONALI

Nel corso degli ultimi cinque anni:

XII Meeting of the European Neurological Society, June 22-26, 2002, Berlin, Germany – Oral session “Higher function disorders”.

XIII Meeting of the European Neurological Society, June 14-18, 2003, Istanbul, Turkey – Oral session “Higher function disorders”.

XIV Congresso Associazione Italiana di Neuroimmunologia, Taormina, 22-25 Ottobre 2003 – sessione orale sulla Sclerosi Multipla

XIV Meeting of the European Neurological Society, June 26-30, 2004, Barcelona, Spain – Oral session “Higher function disorders”, June 29th.

9th Meeting of the Italian Peripheral Nerve Study Group (Joint Meeting with the Italian Association of Miology), Taormina, May 6-8, 2004, sessione orale su neurobiologia

XXXV Annual Meeting of the Italian Neuropathological Association, May 24-26, 2004, Padova, Italy – Session on dementia.

XV Meeting of the European Neurological Society, June 18-22, 2005, Vienna, Austria – Chairman for the oral session “Multiple Sclerosis”, June 20th.

41^o Annual Meeting of the Italian Association of Neuropathology jointly with the French Society of Neuropathology (AINP) – 31^o Annual Meeting of the Italian Association for Research on the Aging Brain (AIRIC), May 26-27, 2005, Saluzzo, Italy – “Inflammation and Alzheimer’s disease: genetic aspects”- Invited Speaker for the symposium organized by AIRIC “Immune system and brain aging pathology”, May 26th, 2005.

“Educational Forum for the Diagnosis and Treatment of Alzheimer’s disease with Cerebrovascular Diseases” organized by Merck Sharp & Dome – personal invitation as Opinion Leader – Friday, May 13th, 2005, Frankfurt, Germany

“Exelon InDDEx Data Review Meeting” organized by Novartis – personal invitation as member of the InDDEx Steering Committee – April 11th, 2005, Miami Beach, USA.

“Approfondimenti monotematici sulla Sclerosi Multipla” 17-18 Marzo 2005, Gallarate

XVI Meeting of the European Neurological Society, June, May 27-31, 2006 Lausanne, Switzerland –oral session “Higher Function Disorders”.

- XVIII Meeting of the European Neurological Society, Nice, June 7-11, 2008 - poster session on dementia

- 20th Meeting of the European Neurological Society, Berlin, Germany, June 19-23, 2010 - oral session on dementia

- 21st Meeting of the European Neurological Society, Lisbon, Portugal, May 28-31, 2011, oral session “Dementia: clinical and neuro.imaging”

- 16th Congress of the European-Federation-of-Neurological-Societies (EFNS) - Stockholm, Sweden September 08-11, 2012 – Poster session on Dementia